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Figure 1 
SEQ ID NO:1 
GATGANCATTTATTAACGCACAACAACAATACAATTACATANGGCAACAATCAAATATA 
CATTCATTTGAAGTGATGATCACAGAAATTTACATACAGATACAACAATTTACATGATG 
GGGGACAAAATGACAATTTTGGGACGGTGGGATGGGATCCTATCATGTCCATGTTGAGG 
TGACGAAGCATCCTTCCATCAGACGTTGTACTCGATCGGCAAGTTCTTGCGGCGCACCA 
TCCCGTCTCCCTGGAACCACTCGAGCTTGAACGTGGTGTCGGCTGGGTCCGGTGTGTTG 
GTCCACTCCGCGGCGGCGGCGGCGCCGGGCGGTTCCGGCACGTTGGTCCACGCCACGGT 
CACACGGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGAAGGCGTCNCAGAANACGGCCA 
CGTTGACAGATTCCTTTGGGCCGANCACTCCGTCCGGCGGGTTCATGTTGATNCGCTTC 
GGTTTGGTGGTCTTGAAGGCGTAGCCGATGCGCTTCGTCCCAAGGTTGATCACNCNCAA 
GTAGTANATGGCTTTGTTGTCGAAGGNACGTTGNAANAGATCTTCTGCGTGGGCATTGT 
TGCGACGTCCTCTGGTGGAAGTTGCGCCATTGCTGTTGTTGTCGCTGTTGTCGGGCTGG 
CTTTGTGGGTGCTTGATGTGTGATCGTTGAGAGCGTTGCTTGAAGTGTTGCTGCTATGC 
TGCTGAGTGAGGGGAATGTGCAAAATCCACCTCCTTATATACAAAATTCGGGTGCAAAA 
ATTCATGCAGCAAAAAAAAAGTGTATAAAAGGCGACGGTTTTCTTCACTTTTCACCAGT 
GCCAGCCAGCCTTCAACTCAACGCAACATCAACACCAGTGCGCGCCAAGCTCGTCTACA 
CATTTCGTCGCGACAACTCATCACTGATCACAGAAATTTACATACAGATACAACAATTT 
ACATGATGGGGGACAAAATGACAATTTTGGGACGGTGGGATGGGATCCTATCATGTCCA 
TGTTGAGGTGACGAAGCATCCTTCCATCAGACGTTGTACTCGATCGGCAAGTTCTTGCG 
GCGCACCATCCCGTCTCCCTGGAACCACTCGAGCTTGAACGCGGTGACCGGCAGGGCCC 
GGCGTGTTGGTCCACTCCACGGCGGCGGTGGCGCCGGGAGGCTNCNCGTGTTGGTCCAC 
TCCACGGTCACACGGTCGCCCTTGGGTGTCCTCGCTTNACCTNCNTNTNCGTTTNNNNT 
GNTATTTTGCCGNACTGN 

U.S. Patent Sep. 28, 2010 Sheet 3 of 17 US 7.803,984 B2 
Figure 3 
SEQ ID NO:5 
CTGCA GGCCTTCAAGACCACCAAACCGAAGCGNATCAACATGAACCCGCC 
GGACGGAGTGNTCGGCCCAAAGGAATCTGTCAACGTGGCCGTNTTCTGNG 
ACGCCTTCGACCCCGGCAGCGAGGACACCAAGGACGACCGTGTGACCGTG 
GCGTGGACCAACGTGCCGGAACCGCCCGGCGCCGCCGCCGCCGCGGAGTG 
GACCAACACACCGGACCCAGCCGACACCACGTTCAAGC TCGAG 
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Figure 5 
SEQ ID NO:9 
5 
CCAACCCTGCACAAAATGCTATGATGGGACATCGTGTTAAGGCATGACTGTT 
TTATTTGCAATTGTTATTTTGGATTATTACGATAGATCTTACCTTGGTCGACTT 
TTCGTATGAATTTGTCCGTCACAACCCCTTACAATGCTGATTTTGACGGGGAT 
GAAATGAATTAGCACCTTCCGCAATCACTGGAGACACGGGCAGAAATAAACG 
AAATTGCGATGGTTTTTATTAATTTAAAGCACCAAATATAACCCTTACCTTTT 
CTCTAAAAAGGCATCTCGACAGTTAATTACGCCACAGGCCAACAAGCCAGTG 
ATGGGAATTGTGCAGGACACATTGACCGCAGTTCGAATGATGACTAAACGCG 
ACGTTTTTATTGATTACGCTCGTCTCATGGATTTGTTGATGCATTTGCCAAATT 
GGGATGGAAAAATTCCGCAGCCAGCGATAATCAA ACCCAAGCCACTTTGGAC 
CGGAAAACAAGTGTTTACAAAGATAATTCCAGGTTTTGTCAAATGAAACTTTT 
CCTCCATTCTTTGTTTTGTTCTAACTAAGGCAGTGTCAATGTTATCCGAACAC 
ATTCGACCCATCCGGACGACGAAGACAGCGGACCATACAAATGGATTTCCCC 
TGGCGACACCAAAGTGCTCATTGAGAACAGCGAACTTCTCTCTGGGATAATT 
TGTTCCAAAACTGTTGGCAGAGGTTCCNGAAACCTTCTTCACATTGTCGCATT 
AGAATTGGGTCATCAAATTGCTGCCGAGTTATATGCCA ACATACAAACTGTT 
ATAAACGCATGGCTTCTCGCCGAGGGACACACCATTGGAATTGGTTTCCAATT 
TTACTTTTATTTACAATAATTTTGTTTAACTCTCAGGTGACACAATTGCTGATA 
CTTCCACCTACAGAGATATCCAGGAGACCATAAGAAAGGCCAAACAGGATGT 
CATTGATGTTATCGAGAAAGCTCACAACGATGATNCTCGAGCCGACTNCCCG 
GGAACACACTTCGACAGACTTCGAAAATCAAGTGAACCGAATTNCTG-3 
U.S. Patent Sep. 28, 2010 Sheet 6 of 17 US 7.803,984 B2 
Figure 6 
SEQ ID NO:10 
5’- 
GGCAGTGTCAATGTTATCCGAACACATTCGACCCATCCGGACGACGAAGACA 
GCGGACCATACAAATGGATTTCCCCTGGCGACACCAAAGTGCTCATTGAGAA 
CAGCGAACTTCTCTCTGGGATAATTTGTTCCAAAACTGTTGGCAGAGGTTCCN 
GAAACCTTCTTCACATTGTCGCATTAGAATTGGGTCATCAAATTGCTGCCGAG 
TTATATGCCA ACATACAAACTGTTATAAACGCATGGCTTCTCGCCGAGGGAC 
ACACCATTGGAATTGGT-3 
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Figure 7 
SEQ ID NO:13 
Antisense fragment-285bp 
279bp exon region from above showing the RP2 KpnF1B and RP2 BamirB primers: 
5 
GGCAGTGTCAATGTTATCCGAACACATTCGACCCATCCGGACGACGAAGACA 
GCGGACCATACAAATGGATTTCCCCTGGCGACACCAAAGTGCTCATTGAGAA 
CAGCGAACTTCTCTCTGGGATAATTTGTTCCAAAACTGTTGGCAGAGGTTCCN 
GAAACCTTCTTCACATTGTCGCATTAGAATTGGGTCATCAAATTGCTGCCGAG 
TTATATGCCAACATACAAACTGTTATAAACGCATGGCTTCTCGCCGAGGGAC 
ACACCATTGGAATTGGT-3 
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Figure 8 
SEQ ID NO:14 
Reverse complement of the 279bp exon fragment showing the RP2 KpnF1B and 
RP2 BamRB primers: 
5 
ACCAATTCCAATGGTGTGTCCCTCGGCGAGAAGCCATGCGTTTATAACAGTTT 
GTATGTTGGCATATAACTCGGCAGCAATTTGATGACCCAATTCTAATGCGACA 
ATGTGAAGAAGGTTTCNGGAACCTCTGCCAACAGTTTTGGAACAAATTATCC 
CAGAGAGAAGTTCGCTGTTCTCAATGAGCACTTTGGTGTCGCCAGGGGAAAT 
CCATTTGTATGGTCCGCTGTCTTCGTCGTCCGGATGGGTCGAATGTGTTCGGA 
TAACATTGACACTGCC-3 
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Figure 9 
Cloning strategy for sense RNA polymerase I sequence 
Kpn I Bam HI BamHI Kon I 
5 D 
I Bam H. pp. I 
35s promoter Antisense fragment Nosterminator 
K 
Antisense fragment 
5 3. 
-O- 
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Figure 10 
SEQ ID NO:17 
GGCAGTGTCAATGTTATCCGAACACATTCGACCCATCCGGACGACGAAG 
ACAGCGGACCATACAAATGGATTTCCCCTGGCGACACCAAAGTGCTCATTGA 
GAACAGCGAACTTCTCTCTGGGATAATTTGTTCCAAAACTGTTGGCAGAGGTT 
CCNGA AACCTTCTTCACATTGTCGCATTAGAATTGGGTCATCAAATTGCTGCC 
GAGTTATATGCCA ACATACAAACTGTTATAAACGCATGGCTTCTCGCCGAGG 
GACACACCATTGGAATTGGT 
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Figure 11 
Cloning strategy for sense RNA polymerase II sequence 
Kpn I Sac I Kpn I Sac I 
N 
243bp 42bp 243bp 
35S Nos 
<-- v -D 
Double Stranded RNA Production 
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Figure 12 
SEQ ID NO:18 
Sp6 
CAAGAAACGATGGTCCCAGGTGATGTACATGTACTTTTTGCTCGGGCATCGAATTATGG 
ACTCACATTTGAGCGTAGAAGACAAACAATTGCAGGTCTTTTGAGCCTAAATTTTGCCC 
TCGTGGAATCTGTGCAATAATTCAATGTTCGCACCGATGCTTAGGCTGACAACACATAT 
ATTCTCGCCATTGATGGCGATTCCAAATTCGAACCAGCGGCAGTGATTCGTCTTTTACA 
TCTGATGAACTTGAAAAGCGACGTTGGCTGTGCGTGCGGAAGAATCCATCCGATTGGAG 
AAGGTGTGCTATCCTTCCCATTAATGGTGAATTTCTTACCATTCCCCAGGGGTCATGGT 
TTGGTACCAAAAGTTCGAGTACGCAATCGCCCATTGGTTCCAAAAGGCTGCTGAGCATG 
TGTTCGGCTGTGTTTTGTGTGCCCCCGGTAGCTTCTCTCTGTTTCGTGCTTCTGCTCTC 
ATGGATGACAATGTGATGCACAAATACACCAAAANTGCCTCCGAACCNACGACNATTTT 
GTTCAGTATTGATCAAGGCGAAGACCCGAGGA-T7 
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Figure 13. Soybean cyst production on transgenic lines vs. control plants as functional of 
cysts per plant. 
Experiment 1 Experiment 2 
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Experiment 1 Experiment 2 
Figure 14. Soybean cyst production on transgenic lines vs. control plants as 
functional of cysts per gram of root tissue. “*” indicates data is significant. 
  
  
  
U.S. Patent Sep. 28, 2010 Sheet 15 Of 17 US 7.803,984 B2 
Experiment 1 Experiment 2 
Figure 15. Soybean cyst nematode egg production on transgenic lines vs. 
control plants as an average number of eggs per plant. “*” indicates data is 
significant. 
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i 
Experiment 1 Experiment 2 
Figure 16. Soybean cyst nematode egg production on transgenic lines vs. control plants 
as an average number of eggs per gram of root. indicates data is significant. 
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Experiment 1 Experiment 2 
Figure 17. Soybean cyst nematode egg production on transgenic lines vs. control plants 
as an average number of eggs per cyst. 
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1. 
COMPOSITIONS AND METHODS FOR 
CONTROLLING PLANT PARASITIC 
NEMATODES 
This application claims the benefit of U.S. Provisional 
Application 60/395,153, filed Jul. 10, 2002. 
This invention was made with government Support under 
Hatch Grant No. KS699 awarded by CRSEES. The Govern 
ment has certain rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to compositions and methods 
for controlling nematode infestation of plants or animals. In 
particular, the present invention provides vectors comprising 
sequences designed to control nematodes by RNA interfer 
ence (RNAi) and transgenic plants transformed with Such 
VectOrS. 
BACKGROUND OF THE INVENTION 
The soybean cyst nematode (SCN), Heterodera glycines, is 
the primary biotic factor limiting Soybean production in the 
United States, accounting for 40% of total disease losses 
(Wrather, J. A., Anderson, T. R., Arsyad, D. M., Gai, J., 
Ploper, L. D., Porta-Puglia, A., Ram, H. H., Yorinori, J. T. 
1997. Soybean disease loss estimates for the top 10 soybean 
producing countries in 1994. Plant Disease 81:107-110). The 
nematode is a relatively recent introduction to Kansas (Sim, 
T., IV., and Todd, T. C. 1986. First field observation of the 
soybean cyst nematode in Kansas. Plant Disease 70:603), yet 
its present distribution encompasses 40 counties across six 
of the nine state districts. Based on the results of an extensive 
grower sampling program (SCN Coalition), approximately 
10% of the state's soybean production fields are estimated to 
be infested with H. glycines, with nematode prevalence in 
several areas exceeding 40%. Yield losses in individual 
infested fields in Kansas range from 10% to 40%, depending 
on environment (Todd, T. C. Schapaugh, W. T., Long, J. H., 
and Holmes, B. 1995. Field response of soybean in maturity 
groups III-V to Heterodera glycines in Kansas. Supplement 
to the Journal of Nematology 27:628-633.). 
Nonhost crops and resistant varieties are the most widely 
used management strategies for SCN. Both effectively reduce 
nematode population densities, but declines in the North Cen 
tral region are relatively slow and elimination unlikely. Resis 
tance, while readily available for the most common variants 
(races) of SCN, has a narrow genetic base (~85% of resistant 
varieties derive their resistance from a single source), and is 
limited or unavailable for Some populations. In addition, 
adaptation of nematode populations to resistant varieties 
poses a significant threat to the long-term management of this 
pest (Holmes, B.A., Todd, T. C., and Schapaugh, W. T. 1999. 
Effect of resistance source on SCN populations. National 
Soybean Cyst Nematode Conference, Orlando, Fla., Jan. 7-8, 
1999: Young, L. D. 1998. Managing soybean resistance to 
Heterodera glycines. Supplement to the Journal of Nematol 
ogy 30:525-529). 
Novel approaches to SCN management are needed to 
complement current strategies, and prolong the effectiveness 
of available resistance genes. 
SUMMARY OF THE INVENTION 
The present invention relates to compositions and methods 
for controlling nematode infestation of plants or animals. In 
particular, the present invention provides vectors comprising 
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2 
sequences designed to control nematodes by RNA interfer 
ence (RNAi) and transgenic plants transformed with Such 
VectOrS. 
Accordingly, in Some embodiments, the present invention 
provides transgenic plants comprising heterologous nucleic 
acid sequences encoding a double stranded nematode RNA 
sequence, wherein said double stranded RNA sequence 
inhibits the proliferation of nematodes ingesting said double 
Stranded nematode RNA sequence. The present invention is 
not limited to any particular expression constructor construct 
design. Indeed, the use of a variety of constructs and designs 
are contemplated. In some embodiments, the heterologous 
nucleic acid sequences are operably linked to the same pro 
moter. In other embodiments, the heterologous nucleic acid 
sequences are operably linked to separate or different pro 
moter sequences. In still other embodiments, the heterolo 
gous nucleic acid sequences are separated by a loop sequence. 
In some embodiments, the promoter is a tissue specific pro 
moter, while in other embodiments the promoter is a consti 
tutive promoter. The present invention is not limited to the use 
of any particular heterologous nucleic acid sequence. Indeed, 
the use of a variety of sequences is contemplated, including, 
but not limited to those that complementary to an RNA 
sequence selected from the group consisting of nematode 
Major sperm protein, RNA polymerase II, and Chitin syn 
thase RNA sequences. In other embodiments, the sequences 
are selected from Tables 1 or 2, supra. Likewise, the present 
invention is not limited to heterologous nucleic acid 
sequences of any particular length. Indeed, heterologous 
nucleic acid sequences of varying lengths may be utilized, 
including those from about 21 bases in length to the full 
length of the target RNA. In still further embodiments, the 
present invention provides plant tissue or material from the 
foregoing transgenic plants. The present invention is not lim 
ited to any particular tissue or material. Indeed, a variety of 
plant tissues and materials are contemplated. Accordingly, in 
Some embodiments, the present invention provides seeds, 
leaves, roots, or processed materials derived from the forego 
ing transgenic plants. 
In some embodiments, the present invention provides vec 
tors comprising heterologous nucleic acid sequences encod 
ing a double stranded nematode RNA sequence, wherein said 
double stranded RNA sequence inhibits the proliferation of 
nematodes ingesting said double stranded RNA sequence. 
The present invention is not limited to any particular vector or 
vector design. Indeed, the use of a variety of vectors and 
designs are contemplated. In some embodiments, the heter 
ologous nucleic acid sequences are operably linked to the 
same promoter. In other embodiments, the heterologous 
nucleic acid sequences are operably linked to separate or 
different promoter sequences. In still other embodiments, the 
heterologous nucleic acid sequences are separated by a loop 
sequence. In some embodiments, the promoter is a tissue 
specific promoter, while in other embodiments the promoter 
is a constitutive promoter. The present invention is not limited 
to the use of any particular heterologous nucleic acid 
sequence. Indeed, the use of a variety of sequences is con 
templated, including, but not limited to those that comple 
mentary to an RNA sequence selected from the group con 
sisting of nematode Major sperm protein, RNA polymerase 
II, and Chitin synthase RNA sequences. In some embodi 
ments, the double stranded nematode RNA is complementary 
to an embryonic lethal phenotype gene. In further embodi 
ments, the double stranded nematode RNA is complementary 
to a sterile phenotype gene. In other embodiments, the 
sequences are selected from Tables 1 or 2, Supra. Likewise, 
the present invention is not limited to heterologous nucleic 
US 7,803,984 B2 
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acid sequences of any particular length. Indeed, heterologous 
nucleic acid sequences of varying lengths may be utilized, 
including those from about 21 bases in length to the full 
length of the target RNA. In still further embodiments, the 
present invention provides a transgenic plant comprising the 
foregoing vectors. In other embodiments, the present inven 
tion provides animal feeds comprising plant tissue from the 
foregoing transgenic plants. In some embodiments, the plant 
tissue is selected from seeds and leaves. In still further 
embodiments, the present invention provides pharmaceutical 
compositions comprising materials derived from the forego 
ing transgenic plants. 
Instill further embodiments, the present invention provides 
methods of creating transgenic plants comprising transfect 
ing a plant or plant tissue with the foregoing vector. In other 
embodiments, the present invention provides the transgenic 
plant produced by this process. In some embodiments, the 
methods further comprises harvesting the transgenic material 
and using the transgenic plant material to produce a pharma 
ceutical composition or animal feed. The present invention 
also provides the pharmaceutical compositions and animal 
feeds produced by these processes. 
In still other embodiments, the present invention provides 
methods for controlling nematodes comprising: a) providing 
transgenic plant tissue comprising heterologous DNA 
sequences encoding a double stranded nematode RNA; and b) 
growing said transgenic plant so that said double stranded 
nematode RNA is expressed in plant tissue; wherein the pro 
liferation of nematodes feeding on said plant tissue is reduced 
as compared to nematodes feeding on non-transgenic plant 
tissue. The present invention is not limited to inhibiting the 
proliferation of any particular type of nematodes. Indeed, the 
inhibition of proliferation of a number of different types of 
nematodes is contemplated, including, but not limited to plant 
parasitic nematodes and animal parasitic nematodes. In some 
preferred embodiments, the double stranded nematode RNA 
is orally active to prevent the proliferation of nematodes. 
Accordingly, in Some embodiment the nematodes orally 
ingest said double stranded nematode RNA. The present 
invention is not limited to the use of any particular expression 
vector or vector design. Indeed, the use of a variety of vectors 
and designs are contemplated. In some embodiments, the 
heterologous nucleic acid sequences are operably linked to 
the same promoter. In other embodiments, the heterologous 
nucleic acid sequences are operably linked to separate or 
different promoter sequences. In still other embodiments, the 
heterologous nucleic acid sequences are separated by a loop 
sequence. In some embodiments, the promoter is a tissue 
specific promoter, while in other embodiments the promoter 
is a constitutive promoter. The present invention is not limited 
to the use of any particular heterologous nucleic acid 
sequence. Indeed, the use of a variety of sequences is con 
templated, including, but not limited to those that comple 
mentary to an RNA sequence selected from the group con 
sisting of nematode Major sperm protein, RNA polymerase 
II, and Chitin synthase RNA sequences. In some embodi 
ments, the double stranded nematode RNA is complementary 
to an embryonic lethal phenotype gene. In further embodi 
ments, the double stranded nematode RNA is complementary 
to a sterile phenotype gene. In other embodiments, the 
sequences are selected from Tables 1 or 2, Supra. Likewise, 
the present invention is not limited to heterologous nucleic 
acid sequences of any particular length. Indeed, heterologous 
nucleic acid sequences of varying lengths may be utilized, 
including those from about 21 bases in length to the full 
length of the target RNA. In some embodiments, the double 
Stranded nematode RNA is complementary to an embryonic 
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lethal phenotype gene. In further embodiments, the double 
stranded nematode RNA is complementary to a sterile phe 
notype gene. In still further embodiments, the nematodes 
feeding on said plant tissue are killed. 
In some embodiments, the present invention provides a 
transgenic plant expressing a heterologous double stranded 
nematode RNA sequence at a level Such that nematodes 
ingesting said heterologous double stranded nematode RNA 
sequences exhibit decreased proliferation as compared to 
nematodes feeding on non-transgenic plants. 
Instill further embodiments, the present invention provides 
pharmaceutical compositions comprising plant material 
derived from the foregoing transgenic plants. 
In some embodiments, the present invention provides for 
the use of transgenic plant material comprising a double 
stranded nematode RNA sequence to inhibit the proliferation 
of parasitic nematodes in an animal or plant host. 
Instill further embodiments, the present invention provides 
compositions according to the claims as Substantially 
described in the application herein with reference to the fig 
ures and/or the specification. 
DESCRIPTION OF THE FIGURES 
FIG. 1 is the sequence for H. glycines Major sperm protein 
(SEQID NO:1). 
FIG. 2A is a subsequence of H. glycines Major sperm 
protein (SEQ ID NO:4). 
FIG. 2B is a subsequence of H. glycines Major sperm 
protein (SEQ ID NO:45). 
FIG. 3 is the reverse complement (SEQID NO:5) of SEQ 
ID NO:4. 
FIG. 4 is the assembled MSPi sequence (SEQID NO:6). 
FIG. 5 is the sequence for H. glycines RNA polymerase II 
(SEQ ID NO:9). 
FIG. 6 provides a 279 base pair exon (SEQIDNO:10) from 
the RNA polymerase II gene of H. glycines. 
FIG. 7 is a 285 bp sequence (SEQ ID NO:13) prepared 
from SEQID NO:10. 
FIG. 8 is the reverse complement (SEQID NO:14) of SEQ 
ID NO:13. 
FIG. 9 provides a pictorial representation of the cloning 
strategy for the RNA polymerase II RNAi construct. 
FIG.10 provides the sense sequence (SEQID NO:17) used 
in the RNA polymerase II RNAi construct. 
FIG. 11 provides a pictorial depiction of the cloning strat 
egy for the RNA polymerase II RNAi construct. 
FIG. 12 provides the sequence for H. glycines Chitin syn 
thase. 
FIG. 13 provides a graph of soybean cyst production on 
transgenic lines vs. control plants as functional of cysts per 
plant. 
FIG. 14 provides a graph of Soybean cyst production on 
transgenic lines vs. control plants as functional of cysts per 
gram of root tissue. “*” indicates data is significant. 
FIG. 15 provides a graph of soybean cyst nematode egg 
production on transgenic lines vs. control plants as an average 
number of eggs per plant. “*” indicates data is significant. 
FIG. 16 provides a graph of soybean cyst nematode egg 
production on transgenic lines vs. control plants as an average 
number of eggs per gram of root. “*” indicates data is signifi 
Cant. 
FIG. 17 provides a graph of soybean cyst nematode egg 
production on transgenic lines vs. control plants as an average 
number of eggs per cyst. 
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DEFINITIONS 
To facilitate an understanding of the present invention, a 
number of terms and phrases as used herein are defined 
below: 
The term “plant is used in it broadest sense. It includes, 
but is not limited to, any species of woody, ornamental or 
decorative, crop or cereal, fruit or vegetable plant, and pho 
tosynthetic green algae (e.g., Chlamydomonas reinhardtii). It 
also refers to a plurality of plant cells that are largely differ 
entiated into a structure that is present at any stage of a plants 
development. Such structures include, but are not limited to, 
a fruit, shoot, stem, leaf, flower petal, etc. The term “plant 
tissue' includes differentiated and undifferentiated tissues of 
plants including those present in roots, shoots, leaves, pollen, 
seeds and tumors, as well as cells in culture (e.g., single cells, 
protoplasts, embryos, callus, etc.). Plant tissue may be in 
planta, in organ culture, tissue culture, or cell culture. The 
term "plant part as used herein refers to a plant structure, a 
plant organ, or a plant tissue. 
The term “crop' or “crop plant' is used in its broadest 
sense. The term includes, but is not limited to, any species of 
plant or algae edible by humans or used as a feed for animals 
or used, or consumed by humans, or any plant or algae used in 
industry or commerce. 
The term plant cell “compartments or organelles' is used in 
its broadest sense. The term includes but is not limited to, the 
endoplasmic reticulum, Golgi apparatus, trans Golgi net 
work, plastids including chloroplasts, proplastids, and leuco 
plasts, sarcoplasmic reticulum, glyoxysomes, mitochondrial, 
chloroplast, and nuclear membranes, and the like. 
As used herein, the term “Major sperm protein (MSP)” 
when used in reference to a protein or nucleic acid refers to a 
protein or nucleic acid encoding a protein that shares greater 
than about 50% identity with any of SEQID NOS: 1,4-6, and 
25-30. Thus, the term MSP encompasses both proteins that 
are identical to wild-type MSP and those that are derived from 
wild type MSP protein (e.g., variants of MSP). 
As used herein, the terms "Major sperm protein gene' and 
“Major sperm protein nucleic acid sequence” refer to the full 
length H. glycines Major sperm protein sequence, as well as 
sequence provided as SEQ ID NOS: 1, 4-6, and 25-30, 
sequences which bind to SEQ ID NOS: 1, 4-6, and 25-30 
under conditions of high Stringency, and nematode Major 
sperm protein sequences available in public databases. These 
terms encompass fragments of the MSP sequences and 
include DNA, cDNA, and RNA (e.g., mRNA) sequences. 
As used herein, the term “RNA polymerase II” when used 
in reference to a protein or nucleic acid refers to a protein or 
nucleic acid encoding a protein that shares greater than about 
50% identity with any of SEQID NOS: 9, 10, 13, 14, 17 and 
31-37. Thus, the term RNA polymerase II encompasses both 
proteins that are identical to wild-type RNA polymerase II 
and those that are derived from wild type RNA polymerase II 
protein (e.g., variants of RNA polymerase II). 
As used herein, the terms “RNA polymerase II gene' and 
“RNA polymerase II nucleic acid sequence” refer to the full 
length H. glycines RNA polymerase II protein sequence, as 
well as sequence provided as SEQID NOS: SEQID NOS:9, 
10, 13, 14, 17 and 31-37, sequences which bind to SEQ ID 
NOS: SEQID NOS: 9, 10, 13, 14, 17 and 31-37 under con 
ditions of high Stringency, and nematode RNA polymerase II 
sequences available in public databases. These terms encom 
pass fragments of the RNA polymerase II sequences and 
include DNA, cDNA, and RNA (e.g., mRNA) sequences. 
As used herein, the term "Chitin synthase' when used in 
reference to a protein or nucleic acid refers to a protein or 
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nucleic acid encoding a protein that shares greater than about 
50% identity with any of SEQID NOS: 18 and 38-44. Thus, 
the term Chitin synthase encompasses both proteins that are 
identical to wild-type Chitin synthase and those that are 
derived from wild type Chitin synthase protein (e.g., variants 
of Chitin synthase). 
As used herein, the terms “Chitin synthase gene' and 
“Chitin synthase nucleic acid sequence” refer to the full 
length H. glycines Chitin synthase protein sequence, as well 
as sequence provided as SEQ ID NOS: 18 and 38-44, 
sequences which bind to SEQID NOs: SEQID NOS: 18 and 
38-44 under conditions of high Stringency, and nematode 
Chitin synthase sequences available in public databases. 
These terms encompass fragments of the Chitin synthase 
sequences and include DNA, cDNA, and RNA (e.g., mRNA) 
Sequences. 
The term “host cell refers to any cell capable of replicating 
and/or transcribing and/or translating a heterologous gene. 
The term "heterologous, when used in reference to DNA 
sequences or genes, means a DNA sequence encoding a pro 
tein, polypeptide, RNA, or a portion of any thereof, whose 
exact amino acid sequence is not normally found in the host 
cell, but is introduced by standard gene transfer techniques. 
The term “nematode' as used herein refers to worms that 
are members of the phylum Nemata. 
The term “RNA interference’ or “RNAi refers to the 
silencing or decreasing of gene expression by iRNA or siR 
NAS. It is the process of sequence-specific, post-transcrip 
tional gene silencing in animals and plants, initiated by iRNA 
that is homologous in its duplex region to the sequence of the 
silenced gene. The gene may be endogenous or exogenous to 
the organism, present integrated into a chromosome or 
present in a transfection vector that is not integrated into the 
genome. The expression of the gene is either completely or 
partially inhibited. RNAi may also be considered to inhibit 
the function of a target RNA; the function of the target RNA 
may be complete or partial. 
The term “interfering RNA (iRNA) refers to a double 
stranded RNA molecule that mediates RNA interference 
(RNAi). At least one strand of the duplex or double-stranded 
region of an iRNA is substantially homologous to or Substan 
tially complementary to a target RNA molecule. The strand 
complementary to a target RNA molecule is the “antisense 
strand; the strand homologous to the target RNA molecule is 
the “sense strand, and is also complementary to the iRNA 
antisense Strand. iRNAS may also contain additional 
sequences; non-limiting examples of such sequences include 
linking sequences, or loops, as well as stem and other folded 
Structures. 
The iRNA can serve as a source of siRNA. siRNAs gener 
ally comprise a duplex, or double-stranded region, of about 
18-25 nucleotides long; often siRNAs contain from about two 
to four unpaired nucleotides at the 3' end of each strand. At 
least one strand of the duplex or double-stranded region of a 
siRNA is substantially homologous to or substantially 
complementary to a target RNA molecule. The strand 
complementary to a target RNA molecule is the “antisense 
strand; the strand homologous to the target RNA molecule is 
the “sense strand, and is also complementary to the siRNA 
antisense Strand. SiRNAS may also contain additional 
sequences; non-limiting examples of such sequences include 
linking sequences, or loops, as well as stem and other folded 
structures. SiRNAS appear to function as key intermediaries in 
triggering RNA interference in invertebrates and in verte 
brates, and in triggering sequence-specific RNA degradation 
during post-transcriptional gene silencing in plants. 
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The term “target RNA molecule' refers to an RNA mol 
ecule to which at least one strand of the short double-stranded 
region of an iRNA is homologous or complementary. Typi 
cally, when Such homology or complementary is about 100%, 
the siRNA is able to silence or inhibit expression of the target 
RNA molecule. Although it is believed that processed mRNA 
is a target of siRNA, the present invention is not limited to any 
particular hypothesis, and Such hypotheses are not necessary 
to practice the present invention. Thus, it is contemplated that 
other RNA molecules may also be targets of siRNA. Such 
targets include unprocessed mRNA, ribosomal RNA, and 
viral RNA genomes. 
As used herein, the term “loop sequence” refers to a nucleic 
acid sequence that is placed between two nucleic sequences 
that are complementary to each other and which forms a loops 
when the complementary nucleic acid sequences hybridize to 
one another. 
The term “nematode target RNA as used herein refers to 
an RNA that is expressed in a nematode. 
The term “double stranded nematode RNA sequence' 
refers to an iRNA that is specific for a nematode target RNA. 
The term “inhibits the proliferation of nematodes' refers to 
a reduction in nematode parasitism of a host organism. The 
inhibition of proliferation can be mediated in a variety of 
ways, including, but not limited to, decreasing the fitness of 
the nematode by decreasing or inhibiting the expression of 
genes required for nematode fitness (e.g., RNA polymerase 
II) or inhibiting genes required for reproduction (e.g., Major 
sperm protein or Chitin synthase). A variety of assays may be 
used to measure proliferation, including, but not limited to 
measuring the number of roots cysts that develop in plants 
exposed to nematodes. 
As used herein, the term "orally active to prevent the pro 
liferation of nematodes' refers to a double stranded nematode 
RNA sequence that inhibits the proliferation of nematodes 
when orally ingested by the nematodes. 
The terms “protein’ and “polypeptide' refer to compounds 
comprisingamino acids joined via peptide bonds and are used 
interchangeably. 
As used herein, “amino acid sequence” refers to an amino 
acid sequence of a protein molecule. “Amino acid sequence' 
and like terms, such as “polypeptide' or “protein.” are not 
meant to limit the amino acid sequence to the complete, native 
amino acid sequence associated with the recited protein mol 
ecule. Furthermore, an 'amino acid sequence can be 
deduced from the nucleic acid sequence encoding the protein. 
The term “portion' when used in reference to a protein (as 
in “a portion of a given protein') refers to fragments of that 
protein. The fragments may range in size from four amino 
acid residues to the entire amino sequence minus one amino 
acid. 
The term “homology' when used in relation to amino acids 
refers to a degree of similarity or identity. There may be 
partial homology or complete homology (i.e., identity). 
“Sequence identity” refers to a measure of relatedness 
between two or more proteins, and is given as a percentage 
with reference to the total comparison length. The identity 
calculation takes into account those amino acid residues that 
are identical and in the same relative positions in their respec 
tive larger sequences. Calculations of identity may be per 
formed by algorithms contained within computer programs. 
The term “homolog’ or “homologous' when used in ref 
erence to a polypeptide refers to a high degree of sequence 
identity between two polypeptides, or to a high degree of 
similarity between the three-dimensional structure or to a 
high degree of similarity between the active site and the 
mechanism of action. In a preferred embodiment, a homolog 
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has a greater than 60% sequence identity, and more preferable 
greater than 75% sequence identity, and still more preferably 
greater than 90% sequence identity, with a reference 
Sequence. 
The terms “variant' and “mutant” when used in reference 
to a polypeptide refer to an amino acid sequence that differs 
by one or more amino acids from another, usually related 
polypeptide. The variant may have "conservative changes, 
wherein a Substituted amino acid has similar structural or 
chemical properties (e.g., replacement of leucine with isoleu 
cine). More rarely, a variant may have “non-conservative' 
changes (e.g., replacement of a glycine with a tryptophan). 
Similar minor variations may also include amino acid dele 
tions or insertions (in other words, additions), or both. Guid 
ance in determining which and how many amino acid resi 
dues may be substituted, inserted or deleted without 
abolishing biological activity may be found using computer 
programs well known in the art, for example, DNAStar soft 
ware. Variants can be tested in functional assays. Preferred 
variants have less than 10%, and preferably less than 5%, and 
still more preferably less than 2% changes (whether substi 
tutions, deletions, and so on). 
The term “gene' refers to a nucleic acid (e.g., DNA or 
RNA) sequence that comprises coding sequences necessary 
for the production of an RNA, or a polypeptide or its precur 
Sor (e.g., proinsulin). A functional polypeptide can be 
encoded by a full length coding sequence or by any portion of 
the coding sequence as long as the desired activity or func 
tional properties (e.g., enzymatic activity, ligand binding, 
signal transduction, etc.) of the polypeptide are retained. The 
term “portion” when used in reference to a gene refers to 
fragments of that gene. The fragments may range in size from 
a few nucleotides to the entire gene sequence minus one 
nucleotide. Thus, “a nucleotide comprising at least a portion 
of a gene' may comprise fragments of the gene or the entire 
gene. 
The term “gene' also encompasses the coding regions of a 
structural gene and includes sequences located adjacent to the 
coding region on both the 5' and 3' ends for a distance of about 
1kb on either end Such that the gene corresponds to the length 
of the full-length mRNA. The sequences which are located 5' 
of the coding region and which are present on the mRNA are 
referred to as 5' non-translated sequences. The sequences 
which are located 3' or downstream of the coding region and 
which are present on the mRNA are referred to as 3' non 
translated sequences. The term 'gene' encompasses both 
cDNA and genomic forms of a gene. A genomic form or clone 
of a gene contains the coding region interrupted with non 
coding sequences termed “introns' or “intervening regions' 
or “intervening sequences.” Introns are segments of a gene 
which are transcribed into nuclear RNA (hnRNA); introns 
may contain regulatory elements such as enhancers. Introns 
are removed or “spliced out from the nuclear or primary 
transcript; introns therefore are absent in the messenger RNA 
(mRNA) transcript. The mRNA functions during translation 
to specify the sequence or order of amino acids in a nascent 
polypeptide. 
In addition to containing introns, genomic forms of a gene 
may also include sequences located on both the 5' and 3' end 
of the sequences that are present on the RNA transcript. These 
sequences are referred to as “flanking sequences or regions 
(these flanking sequences are located 5' or 3' to the non 
translated sequences present on the mRNA transcript). The 5' 
flanking region may contain regulatory sequences such as 
promoters and enhancers that control or influence the tran 
Scription of the gene. The 3' flanking region may contain 
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sequences that direct the termination of transcription, post 
transcriptional cleavage and polyadenylation. 
The term "heterologous gene' refers to a gene encoding a 
factor that is not in its natural environment (i.e., has been 
altered by the hand of man). For example, a heterologous 5 
gene includes a gene from one species introduced into 
another species. A heterologous gene also includes a gene 
native to an organism that has been altered in Some way (e.g., 
mutated, added in multiple copies, linked to a non-native 
promoter or enhancer sequence, etc.). Heterologous genes 10 
may comprise plant gene sequences that comprise cDNA 
forms of a plant gene; the cDNA sequences may be expressed 
in either a sense (to produce mRNA) or anti-sense orientation 
(to produce an anti-sense RNA transcript that is complemen 
tary to the mRNA transcript). Heterologous genes are distin- 15 
guished from endogenous plant genes in that the heterologous 
gene sequences are typically joined to nucleotide sequences 
comprising regulatory elements such as promoters that are 
not found naturally associated with the gene for the protein 
encoded by the heterologous gene or with plant gene 20 
sequences in the chromosome, or are associated with portions 
of the chromosome not found in nature (e.g., genes expressed 
in loci where the gene is not normally expressed). 
The term "oligonucleotide' refers to a molecule comprised 
of two or more deoxyribonucleotides or ribonucleotides, 25 
preferably more than three, and usually more than ten. The 
exact size will depend on many factors, which in turn depends 
on the ultimate function or use of the oligonucleotide. The 
oligonucleotide may be generated in any manner, including 
chemical synthesis, DNA replication, reverse transcription, 30 
or a combination thereof. 
The term “an oligonucleotide having a nucleotide 
sequence encoding a gene' or “a nucleic acid sequence 
encoding a specified polypeptide refers to a nucleic acid 
sequence comprising the coding region of a gene or in other 35 
words the nucleic acid sequence which encodes a gene prod 
uct. The coding region may be present in either a cDNA, 
genomic DNA or RNA form. When present in a DNA form, 
the oligonucleotide may be single-stranded (i.e., the sense 
strand) or double-stranded. Suitable control elements such as 40 
enhancers/promoters, splice junctions, polyadenylation sig 
nals, etc. may be placed in close proximity to the coding 
region of the gene if needed to permit proper initiation of 
transcription and/or correct processing of the primary RNA 
transcript. Alternatively, the coding region utilized in the 45 
expression vectors of the present invention may contain 
endogenous enhancers/promoters, splice junctions, interven 
ing sequences, polyadenylation signals, etc. or a combination 
of both endogenous and exogenous control elements. 
The terms “complementary' and “complementarity” refer 50 
to polynucleotides (i.e., a sequence of nucleotides) related by 
the base-pairing rules. For example, for the sequence "A-G- 
T” is complementary to the sequence “T-C-A. Complemen 
tarity may be “partial.” in which only some of the nucleic 
acids bases are matched according to the base pairing rules. 55 
Or, there may be “complete' or “total complementarity 
between the nucleic acids. The degree of complementarity 
between nucleic acid strands has significant effects on the 
efficiency and strength of hybridization between nucleic acid 
Strands. This is of particular importance in amplification reac- 60 
tions, as well as detection methods which depend upon bind 
ing between nucleic acids. 
The term “homology' when used in relation to nucleic 
acids refers to a degree of complementarity. There may be 
partial homology or complete homology (i.e., identity). 65 
“Sequence identity” refers to a measure of relatedness 
between two or more nucleic acids, and is given as a percent 
10 
age with reference to the total comparison length. The iden 
tity calculation takes into account those nucleotide residues 
that are identical and in the same relative positions in their 
respective larger sequences. Calculations of identity may be 
performed by algorithms contained within computer pro 
grams such as “GAP’ (Genetics Computer Group, Madison, 
Wis.) and “ALIGN” (DNAStar, Madison, Wis.). A partially 
complementary sequence is one that at least partially inhibits 
(or competes with) a completely complementary sequence 
from hybridizing to a target nucleic acid is referred to using 
the functional term “substantially homologous.” The inhibi 
tion of hybridization of the completely complementary 
sequence to the target sequence may be examined using a 
hybridization assay (Southern or Northern blot, solution 
hybridization and the like) under conditions of low strin 
gency. A Substantially homologous sequence or probe will 
compete for and inhibit the binding (i.e., the hybridization) of 
a sequence that is completely homologous to a target under 
conditions of low stringency. This is not to say that conditions 
of low stringency are such that non-specific binding is per 
mitted; low stringency conditions require that the binding of 
two sequences to one another be a specific (i.e., selective) 
interaction. The absence of non-specific binding may be 
tested by the use of a second target which lacks even a partial 
degree of complementarity (e.g., less than about 30% iden 
tity); in the absence of non-specific binding the probe will not 
hybridize to the second non-complementary target. 
When used in reference to a double-stranded nucleic acid 
sequence Such as a cDNA or genomic clone, the term "sub 
stantially homologous' refers to any probe which can hybrid 
ize to either or both strands of the double-stranded nucleic 
acid sequence under conditions of low stringency as 
described infra. 
The term “hybridization” refers to the pairing of comple 
mentary nucleic acids. Hybridization and the strength of 
hybridization (i.e., the strength of the association between the 
nucleic acids) is impacted by Such factors as the degree of 
complementary between the nucleic acids, stringency of the 
conditions involved, the T of the formed hybrid, and the G:C 
ratio within the nucleic acids. A single molecule that contains 
pairing of complementary nucleic acids within its structure is 
said to be “self-hybridized.” 
The term “T” refers to the “melting temperature' of a 
nucleic acid. The melting temperature is the temperature at 
which a population of double-stranded nucleic acid mol 
ecules becomes half dissociated into single strands. The equa 
tion for calculating the T of nucleic acids is well known in 
the art. As indicated by standard references, a simple estimate 
of the T value may be calculated by the equation: T81.5+ 
0.41 (% G+C), when a nucleic acid is in aqueous Solution at 1 
MNaCl (See e.g., Anderson and Young, Quantitative Filter 
Hybridization (1985) in Nucleic Acid Hybridization). Other 
references include more Sophisticated computations that take 
structural as well as sequence characteristics into account for 
the calculation of T. 
As used herein the term “stringency” refers to the condi 
tions oftemperature, ionic strength, and the presence of other 
compounds such as organic solvents, under which nucleic 
acid hybridizations are conducted. With “high stringency’ 
conditions, nucleic acid base pairing will occur only between 
nucleic acid fragments that have a high frequency of comple 
mentary base sequences. Thus, conditions of “low” strin 
gency are often required with nucleic acids that are derived 
from organisms that are genetically diverse, as the frequency 
of complementary sequences is usually less. 
“High stringency conditions” when used in reference to 
nucleic acid hybridization comprise conditions equivalent to 
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binding or hybridization at 42°C. in a solution consisting of 
5xSSPE (43.8 g/l NaCl, 6.9 g/l NaHPO HO and 1.85 g/1 
EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5xDen 
hardt’s reagent and 100 ug/ml denatured salmon sperm DNA 
followed by washing in a solution comprising 0.1 xSSPE, 
1.0% SDS at 42°C. when a probe of about 500 nucleotides in 
length is employed. 
“Medium stringency conditions” when used in reference to 
nucleic acid hybridization comprise conditions equivalent to 
binding or hybridization at 42°C. in a solution consisting of 
5xSSPE (43.8 g/l NaCl, 6.9 g/l NaH2POHO and 1.85 g/1 
EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5xDen 
hardt’s reagent and 100 ug/ml denatured salmon sperm DNA 
followed by washing in a solution comprising 1.0xSSPE, 
1.0% SDS at 42°C. when a probe of about 500 nucleotides in 
length is employed. 
“Low Stringency conditions' comprise conditions equiva 
lent to binding or hybridization at 42°C. in a solution con 
sisting of 5xSSPE (43.8 g/l NaCl, 6.9 g/l NaH2POHO and 
1.85g/1 EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 
5xDenhardt’s reagent 50xDenhardt’s contains per 500 ml: 5 
gFicoll (Type 400, Pharamcia), 5 g BSA (Fraction V: Sigma) 
and 100 ug/ml denatured salmon sperm DNA followed by 
washing in a solution comprising 5xSSPE, 0.1% SDS at 42 
C. when a probe of about 500 nucleotides in length is 
employed. 
It is well known that numerous equivalent conditions may 
be employed to comprise desired stringency conditions; fac 
tors such as the length and nature (DNA, RNA, base compo 
sition) of the probe and nature of the target (DNA, RNA, base 
composition, present in Solution or immobilized, etc.) and the 
concentration of the salts and other components (e.g., the 
presence or absence of formamide, dextran Sulfate, polyeth 
ylene glycol) are considered and the hybridization Solution 
may be varied to generate conditions of low stringency 
hybridization different from, but equivalent to, the above 
listed conditions. In addition, the art knows conditions that 
promote hybridization under conditions of high Stringency 
(e.g., increasing the temperature of the hybridization and/or 
wash steps, the use of formamide in the hybridization solu 
tion, etc.). 
When used in reference to a double-stranded nucleic acid 
sequence Such as a cDNA or genomic clone, the term "sub 
stantially homologous' refers to any probe that can hybridize 
to either or both strands of the double-stranded nucleic acid 
sequence under conditions of low to high Stringency as 
described above. 
When used in reference to a single-stranded nucleic acid 
sequence, the term 'substantially homologous' refers to any 
probe that can hybridize (i.e., it is the complement of) the 
single-stranded nucleic acid sequence under conditions of 
low to high Stringency as described above. 
Amplification' is a special case of nucleic acid replication 
involving template specificity. It is to be contrasted with non 
specific template replication (i.e., replication that is template 
dependent but not dependent on a specific template). Tem 
plate specificity is here distinguished from fidelity of 
replication (i.e., synthesis of the proper polynucleotide 
sequence) and nucleotide (ribo- or deoxyribo-) specificity. 
Template specificity is frequently described in terms of “tar 
get specificity. Target sequences are “targets' in the sense 
that they are sought to be sorted out from other nucleic acid. 
Amplification techniques have been designed primarily for 
this sorting out. 
Template specificity is achieved in most amplification 
techniques by the choice of enzyme. Amplification enzymes 
are enzymes that, under conditions they are used, will process 
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only specific sequences of nucleic acid in a heterogeneous 
mixture of nucleic acid. For example, in the case of Q Brep 
licase, MDV-1 RNA is the specific template for the replicase 
(Kacian et al. (1972) Proc. Natl. Acad. Sci. USA, 69:3038). 
Other nucleic acid will not be replicated by this amplification 
enzyme. Similarly, in the case of T7 RNA polymerase, this 
amplification enzyme has a stringent specificity for its own 
promoters (Chamberlin et al. (1970) Nature, 228:227). In the 
case of T4 DNA ligase, the enzyme will not ligate the two 
oligonucleotides or polynucleotides, where there is a mis 
match between the oligonucleotide or polynucleotide sub 
strate and the template at the ligation junction (Wu and Wal 
lace (1989) Genomics, 4:560). Finally, Taq and Pfu 
polymerases, by virtue of their ability to function at high 
temperature, are found to display high specificity for the 
sequences bounded and thus defined by the primers; the high 
temperature results in thermodynamic conditions that favor 
primer hybridization with the target sequences and not 
hybridization with non-target sequences (H. A. Erlich (ed.) 
(1989) PCR Technology, Stockton Press). 
The term “amplifiable nucleic acid refers to nucleic acids 
that may be amplified by any amplification method. It is 
contemplated that “amplifiable nucleic acid' will usually 
comprise “sample template.” 
The term “sample template” refers to nucleic acid originat 
ing from a sample that is analyzed for the presence of “target' 
(defined below). In contrast, “background template' is used 
in reference to nucleic acid other than sample template that 
may or may not be present in a sample. Background template 
is most often inadvertent. It may be the result of carryover, or 
it may be due to the presence of nucleic acid contaminants 
sought to be purified away from the sample. For example, 
nucleic acids from organisms other than those to be detected 
may be present as background in a test sample. 
The term “primer' refers to an oligonucleotide, whether 
occurring naturally as in a purified restriction digest or pro 
duced synthetically, which is capable of acting as a point of 
initiation of synthesis when placed under conditions in which 
synthesis of a primer extension product which is complemen 
tary to a nucleic acid strand is induced, (i.e., in the presence of 
nucleotides and an inducing agent such as DNA polymerase 
and at a suitable temperature and pH). The primer is prefer 
ably single stranded for maximum efficiency in amplification, 
but may alternatively be double stranded. If double stranded, 
the primer is first treated to separate its strands before being 
used to prepare extension products. Preferably, the primer is 
an oligodeoxyribonucleotide. The primer must be sufficiently 
long to prime the synthesis of extension products in the pres 
ence of the inducing agent. The exact lengths of the primers 
will depend on many factors, including temperature, Source 
of primer and the use of the method. 
The term “polymerase chain reaction” (“PCR) refers to 
the method of K. B. Mullis U.S. Pat. Nos. 4,683, 195, 4,683, 
202, and 4,965,188, that describe a method for increasing the 
concentration of a segment of a target sequence in a mixture 
of genomic DNA without cloning or purification. This pro 
cess for amplifying the target sequence consists of introduc 
ing a large excess of two oligonucleotide primers to the DNA 
mixture containing the desired target sequence, followed by a 
precise sequence of thermal cycling in the presence of a DNA 
polymerase. The two primers are complementary to their 
respective strands of the double stranded target sequence. To 
effect amplification, the mixture is denatured and the primers 
then annealed to their complementary sequences within the 
target molecule. Following annealing, the primers are 
extended with a polymerase so as to form a new pair of 
complementary strands. The steps of denaturation, primer 
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annealing, and polymerase extension can be repeated many 
times (i.e., denaturation, annealing and extension constitute 
one “cycle'; there can be numerous “cycles') to obtain a high 
concentration of an amplified segment of the desired target 
sequence. The length of the amplified segment of the desired 
target sequence is determined by the relative positions of the 
primers with respect to each other, and therefore, this length 
is a controllable parameter. By virtue of the repeating aspect 
of the process, the method is referred to as the “polymerase 
chain reaction’ (hereinafter "PCR). Because the desired 
amplified segments of the target sequence become the pre 
dominant sequences (in terms of concentration) in the mix 
ture, they are said to be “PCR amplified.” 
With PCR, it is possible to amplify a single copy of a 
specific target sequence in genomic DNA to a level detectable 
by several different methodologies (e.g., hybridization with a 
labeled probe; incorporation of biotinylated primers followed 
by avidin-enzyme conjugate detection; incorporation of P 
labeled deoxynucleotide triphosphates, such as dCTP or 
dATP, into the amplified segment). In addition to genomic 
DNA, any oligonucleotide or polynucleotide sequence can be 
amplified with the appropriate set of primer molecules. In 
particular, the amplified segments created by the PCR process 
itselfare, themselves, efficient templates for subsequent PCR 
amplifications. 
The terms “PCR product,” “PCR fragment,” and “amplifi 
cation product” refer to the resultant mixture of compounds 
after two or more cycles of the PCR steps of denaturation, 
annealing and extension are complete. These terms encom 
pass the case where there has been amplification of one or 
more segments of one or more target sequences. 
The term “amplification reagents' refers to those reagents 
(deoxyribonucleotide triphosphates, buffer, etc.), needed for 
amplification except for primers, nucleic acid template, and 
the amplification enzyme. Typically, amplification reagents 
along with other reaction components are placed and con 
tained in a reaction vessel (test tube, microwell, etc.). 
The term “reverse-transcriptase' or “RT-PCR refers to a 
type of PCR where the starting material is mRNA. The start 
ing mRNA is enzymatically converted to complementary 
DNA or “cDNA using a reverse transcriptase enzyme. The 
cDNA is then used as a “template” for a “PCR reaction. 
The term “gene expression” refers to the process of con 
Verting genetic information encoded in a gene into RNA (e.g., 
mRNA, rRNA, tRNA, or snRNA) through “transcription” of 
the gene (i.e., via the enzymatic action of an RNA poly 
merase), and into protein, through “translation” of mRNA. 
Gene expression can be regulated at many stages in the pro 
cess. “Up-regulation” or “activation” refers to regulation that 
increases the production of gene expression products (i.e., 
RNA or protein), while “down-regulation” or “repression' 
refers to regulation that decrease production. Molecules (e.g., 
transcription factors) that are involved in up-regulation or 
down-regulation are often called “activators' and “repres 
sors, respectively. 
The terms “in operable combination”, “in operable order 
and “operably linked’ refer to the linkage of nucleic acid 
sequences in Such a manner that a nucleic acid molecule 
capable of directing the transcription of a given gene and/or 
the synthesis of a desired protein molecule is produced. The 
term also refers to the linkage of amino acid sequences in Such 
a manner so that a functional protein is produced. 
The term “regulatory element” refers to a genetic element 
that controls some aspect of the expression of nucleic acid 
sequences. For example, a promoter is a regulatory element 
that facilitates the initiation of transcription of an operably 
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linked coding region. Other regulatory elements are splicing 
signals, polyadenylation signals, termination signals, etc. 
Transcriptional control signals in eukaryotes comprise 
“promoter” and "enhancer' elements. Promoters and enhanc 
ers consist of short arrays of DNA sequences that interact 
specifically with cellular proteins involved in transcription 
(Maniatis, et al., Science 236:1237, 1987). Promoter and 
enhancer elements have been isolated from a variety of 
eukaryotic sources including genes in yeast, insect, mamma 
lian and plant cells. Promoter and enhancer elements have 
also been isolated from viruses and analogous control ele 
ments, such as promoters, are also found in prokaryotes. The 
selection of a particular promoter and enhancer depends on 
the cell type used to express the protein of interest. Some 
eukaryotic promoters and enhancers have a broad host range 
while others are functional in a limited subset of cell types 
(for review, see Voss, et al., Trends Biochem. Sci., 11:287, 
1986; and Maniatis, et al., supra 1987). 
The terms “promoter element,” “promoter,” or “promoter 
sequence' as used herein, refer to a DNA sequence that is 
located at the 5' end (i.e. precedes) the protein coding region 
of a DNA polymer. The location of most promoters known in 
nature precedes the transcribed region. The promoter func 
tions as a Switch, activating the expression of a gene. If the 
gene is activated, it is said to be transcribed, or participating in 
transcription. Transcription involves the synthesis of mRNA 
from the gene. The promoter, therefore, serves as a transcrip 
tional regulatory element and also provides a site for initiation 
of transcription of the gene into mRNA. 
Promoters may be tissue specific or cell specific. The term 
“tissue specific' as it applies to a promoter refers to a pro 
moter that is capable of directing selective expression of a 
nucleotide sequence of interest to a specific type of tissue 
(e.g., seed tissue) in the relative absence of expression of the 
same nucleotide sequence of interest in a different type of 
tissue (e.g., leave tissue). Tissue specificity of a promoter may 
be evaluated by, for example, operably linking a reporter gene 
to the promoter sequence to generate a reporter construct, 
introducing the reporter construct into the genome of a plant 
Such that the reporter construct is integrated into every tissue 
of the resulting transgenic plant, and detecting the expression 
of the reporter gene (e.g., detecting mRNA, protein, or the 
activity of a protein encoded by the reporter gene) in different 
tissues of the transgenic plant. The detection of a greater level 
of expression of the reporter gene in one or more tissues 
relative to the level of expression of the reporter gene in other 
tissues shows that the promoter is specific for the tissues in 
which greater levels of expression are detected. The term 
“cell type specific' as applied to a promoter refers to a pro 
moter which is capable of directing selective expression of a 
nucleotide sequence of interest in a specific type of cell in the 
relative absence of expression of the same nucleotide 
sequence of interest in a different type of cell within the same 
tissue. The term “cell type specific' when applied to a pro 
moter also means a promoter capable of promoting selective 
expression of a nucleotide sequence of interest in a region 
within a single tissue. Cell type specificity of a promoter may 
be assessed using methods well known in the art, e.g., immu 
nohistochemical staining. Briefly, tissue sections are embed 
ded in paraffin, and paraffin sections are reacted with a pri 
mary antibody that is specific for the polypeptide product 
encoded by the nucleotide sequence of interest whose expres 
sion is controlled by the promoter. A labeled (e.g., peroxidase 
conjugated) secondary antibody that is specific for the pri 
mary antibody is allowed to bind to the sectioned tissue and 
specific binding detected (e.g., with avidin/biotin) by micros 
copy. 
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Promoters may be constitutive or regulatable. The term 
“constitutive' when made in reference to a promoter means 
that the promoter is capable of directing transcription of an 
operably linked nucleic acid sequence in the absence of a 
stimulus (e.g., heat shock, chemicals, light, etc.). Typically, 
constitutive promoters are capable of directing expression of 
a transgene in Substantially any cell and any tissue. Exem 
plary constitutive plant promoters include, but are not limited 
to SD Cauliflower Mosaic Virus (CaMV SD; see e.g., U.S. 
Pat. No. 5,352.605, incorporated herein by reference), man 
nopine synthase, octopine synthase (ocs), Superpromoter (see 
e.g., WO 95/14098), and ubi3 (see e.g., Garbarino and 
Belknap (1994) Plant Mol. Biol. 24:119-127) promoters. 
Such promoters have been used successfully to direct the 
expression of heterologous nucleic acid sequences in trans 
formed plant tissue. 
In contrast, a “regulatable' promoter is one which is 
capable of directing a level of transcription of an operably 
linked nuclei acid sequence in the presence of a stimulus (e.g., 
heat shock, chemicals, light, etc.) which is different from the 
level of transcription of the operably linked nucleic acid 
sequence in the absence of the stimulus. 
The enhancer and/or promoter may be “endogenous” or 
“exogenous” or "heterologous.” An "endogenous enhancer 
or promoter is one that is naturally linked with a given gene in 
the genome. An "exogenous” or "heterologous' enhancer or 
promoter is one that is placed in juxtaposition to a gene by 
means of genetic manipulation (i.e., molecular biological 
techniques) Such that transcription of the gene is directed by 
the linked enhancer or promoter. For example, an endogenous 
promoter in operable combination with a first gene can be 
isolated, removed, and placed in operable combination with a 
second gene, thereby making it a "heterologous promoter” in 
operable combination with the second gene. A variety of such 
combinations are contemplated (e.g., the first and second 
genes can be from the same species, or from different species. 
The presence of “splicing signals' on an expression vector 
often results in higher levels of expression of the recombinant 
transcript in eukaryotic host cells. Splicing signals mediate 
the removal of introns from the primary RNA transcript and 
consist of a splice donor and acceptor site (Sambrook, et al. 
(1989) Molecular Cloning: A Laboratory Manual, 2nd ed., 
Cold Spring Harbor Laboratory Press, New York, pp. 16.7- 
16.8). A commonly used splice donor and acceptor site is the 
splice junction from the 16S RNA of SV40. 
Efficient expression of recombinant DNA sequences in 
eukaryotic cells requires expression of signals directing the 
efficient termination and polyadenylation of the resulting 
transcript. Transcription termination signals are generally 
found downstream of the polyadenylation signal and area few 
hundred nucleotides in length. The term “poly(A) site' or 
"poly(A) sequence' as used herein denotes a DNA sequence 
which directs both the termination and polyadenylation of the 
nascent RNA transcript. Efficient polyadenylation of the 
recombinant transcript is desirable, as transcripts lacking a 
poly(A)tail are unstable and are rapidly degraded. The poly 
(A) signal utilized in an expression vector may be "heterolo 
gous' or "endogenous.” An endogenous poly(A) signal is one 
that is found naturally at the 3' end of the coding region of a 
given gene in the genome. A heterologous poly(A) signal is 
one which has been isolated from one gene and positioned 3' 
to another gene. A commonly used heterologous poly(A) 
signal is the SV40 poly(A) signal. The SV40 poly(A) signal is 
contained on a 237 bp BamHI/BclI restriction fragment and 
directs both termination and polyadenylation (Sambrook, 
supra, at 16.6-16.7). 
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The term “selectable marker” refers to a gene which 
encodes an enzyme having an activity that confers resistance 
to an antibiotic or drug upon the cell in which the selectable 
marker is expressed, or which confers expression of a trait 
which can be detected (e.g., luminescence or fluorescence). 
Selectable markers may be “positive' or “negative.” 
Examples of positive selectable markers include the neomy 
cin phosphotransferase (NPTII) gene which confers resis 
tance to G418 and to kanamycin, and the bacterial hygromy 
cin phosphotransferase gene (hyg), which confers resistance 
to the antibiotic hygromycin. Negative selectable markers 
encode an enzymatic activity whose expression is cytotoxic 
to the cell when grown in an appropriate selective medium. 
For example, the HSV-tkgene is commonly used as a negative 
selectable marker. Expression of the HSV-tk gene in cells 
grown in the presence of gancyclovir or acyclovir is cyto 
toxic; thus, growth of cells in selective medium containing 
gancyclovir or acyclovir selects against cells capable of 
expressing a functional HSVTK enzyme. 
The term “vector refers to nucleic acid molecules that 
transfer DNA segment(s) from one cell to another. The term 
“vehicle' is sometimes used interchangeably with “vector.” 
The terms “expression vector” or “expression cassette' 
refer to a recombinant DNA molecule containing a desired 
coding sequence and appropriate nucleic acid sequences nec 
essary for the expression of the operably linked coding 
sequence in a particular host organism. Nucleic acid 
sequences necessary for expression in prokaryotes usually 
include a promoter, an operator (optional), and a ribosome 
binding site, often along with other sequences. Eukaryotic 
cells are known to utilize promoters, enhancers, and termina 
tion and polyadenylation signals. 
The terms “transfection', “transformation', “transfected 
and “transformed are used interchangeably and refer to the 
introduction of foreign DNA into cells. Transfection may be 
accomplished by a variety of means known to the art includ 
ing calcium phosphate-DNA co-precipitation, DEAE-dext 
ran-mediated transfection, polybrene-mediated transfection, 
glass beads, electroporation, microinjection, liposome 
fusion, lipofection, protoplast fusion, viral infection, biolis 
tics (i.e., particle bombardment) and the like. 
The terms “infecting and “infection' when used with a 
bacterium refer to co-incubation of a target biological sample, 
(e.g., cell, tissue, etc.) with the bacterium under conditions 
Such that nucleic acid sequences contained within the bacte 
rium are introduced into one or more cells of the target bio 
logical sample. 
The term 'Agrobacterium” refers to a soil-borne, Gram 
negative, rod-shaped phytopathogenic bacterium which 
causes crown gall. The term "Agrobacterium' includes, but is 
not limited to, the strains Agrobacterium tumefaciens, (which 
typically causes crown gall in infected plants), and Agrobac 
terium rhizogens (which causes hairy root disease in infected 
host plants). Infection of a plant cell with Agrobacterium 
generally results in the production of opines (e.g., nopaline, 
agropine, octopine etc.) by the infected cell. Thus, Agrobac 
terium strains which cause production of nopaline (e.g., Strain 
LBA4301, C58, A208, GV3101) are referred to as “nopaline 
type Agrobacteria; Agrobacterium strains which cause pro 
duction of octopine (e.g., strain LBA4404, Achs, B6) are 
referred to as "octopine-type Agrobacteria; and Agrobacte 
rium strains which cause production of agropine (e.g., Strain 
EHA105, EHA101, A281) are referred to as “agropine-type” 
Agrobacteria. 
The terms “bombarding, “bombardment,” and “biolistic 
bombardment” refer to the process of accelerating particles 
towards a target biological sample (e.g., cell, tissue, etc.) to 
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effect wounding of the cell membrane of a cell in the target 
biological sample and/or entry of the particles into the target 
biological sample. Methods for biolistic bombardment are 
known in the art (e.g., U.S. Pat. No. 5,584.807, the contents of 
which are incorporated herein by reference), and are com 
mercially available (e.g., the helium gas-driven microprojec 
tile accelerator (PDS-1000/He, BioRad). 
The term “microwounding” when made in reference to 
plant tissue refers to the introduction of microscopic wounds 
in that tissue. Microwounding may be achieved by, for 
example, particle bombardment as described herein. 
The term “transgenic’ when used in reference to a plant or 
fruit or seed (i.e., a “transgenic plant’ or “transgenic fruit' or 
a “transgenic seed') refers to a plant or fruit or seed that 
contains at least one heterologous gene in one or more of its 
cells. The term “transgenic plant material refers broadly to a 
plant, a plant structure, a plant tissue, a plant seed or a plant 
cell that contains at least one heterologous gene in one or 
more of its cells. 
The terms “transformants' or “transformed cells' include 
the primary transformed cell and cultures derived from that 
cell without regard to the number of transfers. All progeny 
may not be precisely identical in DNA content, due to delib 
erate or inadvertent mutations. Mutant progeny that have the 
same functionality as screened for in the originally trans 
formed cell are included in the definition of transformants. 
The term “wild-type' when made in reference to a gene 
refers to a gene that has the characteristics of a gene isolated 
from a naturally occurring source. The term “wild-type' 
when made in reference to a gene product refers to a gene 
product that has the characteristics of a gene product isolated 
from a naturally occurring source. A wild-type gene is that 
which is most frequently observed in a population and is thus 
arbitrarily designated the “normal” or “wild-type' form of the 
gene. In contrast, the term “modified’ or “mutant when 
made in reference to a gene or to a gene product refers, 
respectively, to a gene or to a gene product which displays 
modifications in sequence and/or functional properties (i.e., 
altered characteristics) when compared to the wild-type gene 
or gene product. It is noted that naturally-occurring mutants 
can be isolated; these are identified by the fact that they have 
altered characteristics when compared to the wild-type gene 
or gene product. 
The term “antisense' refers to a deoxyribonucleotide 
sequence whose sequence of deoxyribonucleotide residues is 
in reverse 5' to 3' orientation in relation to the sequence of 
deoxyribonucleotide residues in a sense strand of a DNA 
duplex. A “sense strand of a DNA duplex refers to a strand in 
a DNA duplex that is transcribed by a cell in its natural state 
into a “sense mRNA. Thus an “antisense” sequence is a 
sequence having the same sequence as the non-coding strand 
in a DNA duplex. The term “antisense RNA” refers to a RNA 
transcript that is complementary to all or part of a target 
primary transcript or mRNA and that blocks the expression of 
a target gene by interfering with the processing, transport 
and/or translation of its primary transcript or mRNA. The 
complementarity of an antisense RNA may be with any part 
of the specific gene transcript, i.e., at the 5' non-coding 
sequence, 3' non-coding sequence, introns, or the coding 
sequence. In addition, as used herein, antisense RNA may 
contain regions of ribozyme sequences that increase the effi 
cacy of antisense RNA to block gene expression. “Ribozyme’ 
refers to a catalytic RNA and includes sequence-specific 
endoribonucleases. “Antisense inhibition” refers to the pro 
duction of antisense RNA transcripts capable of preventing 
the expression of the target protein. 
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The term “posttranscriptional gene silencing or “PTGS’ 
refers to silencing of gene expression in plants after transcrip 
tion, and appears to involve the specific degradation of 
mRNAS Synthesized from gene repeats. 
The term “overexpression” refers to the production of a 
gene product in transgenic organisms that exceeds levels of 
production in normal or non-transformed organisms. The 
term "cosuppression” refers to the expression of a foreign 
gene that has substantial homology to an endogenous gene 
resulting in the Suppression of expression of both the foreign 
and the endogenous gene. The term “altered levels' refers to 
the production of gene product(s) in transgenic organisms in 
amounts or proportions that differ from that of normal or 
non-transformed organisms. 
The term “recombinant' when made in reference to a 
nucleic acid molecule refers to a nucleic acid molecule that is 
comprised of segments of nucleic acid joined together by 
means of molecular biological techniques. The term “recom 
binant when made in reference to a protein or a polypeptide 
refers to a protein molecule that is expressed using a recom 
binant nucleic acid molecule. 
The term "isolated when used in relation to a nucleic acid, 
as in “an isolated oligonucleotide' refers to a nucleic acid 
sequence that is identified and separated from at least one 
contaminant nucleic acid with which it is ordinarily associ 
ated in its natural source. Isolated nucleic acid is present in a 
form or setting that is different from that in which it is found 
in nature. 
The term “purified’ refers to molecules, either nucleic or 
amino acid sequences, that are removed from their natural 
environment, isolated or separated. An "isolated nucleic acid 
sequence' is therefore a purified nucleic acid sequence. "Sub 
stantially purified molecules are at least 60% free, preferably 
at least 75% free, and more preferably at least 90% free from 
other components with which they are naturally associated. 
The term “purified’ or “to purify also refer to the removal of 
contaminants from a sample. The removal of contaminating 
proteins results in an increase in the percent of polypeptide of 
interest in the sample. In another example, recombinant 
polypeptides are expressed in plant, bacterial, yeast, or mam 
malian host cells and the polypeptides are purified by the 
removal of host cell proteins; the percent of recombinant 
polypeptides is thereby increased in the sample. 
The term “sample' is used in its broadest sense. In one 
sense it can refer to a plant cell or tissue. In another sense, it 
is meant to include a specimen or culture obtained from any 
Source, as well as biological and environmental samples. 
Biological samples may be obtained from plants or animals 
(including humans) and encompass fluids, Solids, tissues, and 
gases. Environmental samples include environmental mate 
rial Such as Surface matter, soil, water, and industrial samples. 
These examples are not to be construed as limiting the sample 
types applicable to the present invention. 
DESCRIPTION OF THE INVENTION 
The present invention relates to compositions and methods 
for controlling nematode infestation of plants or animals. In 
particular, the present invention provides vectors comprising 
sequences designed to control nematodes by RNA interfer 
ence (RNAi) and transgenic plants transformed with Such 
vectors. The compositions and methods of the present inven 
tion can be used to inhibit the growth and reproduction of a 
number of nematodes species, including, but not limited to 
plant parasitic nematodes and nematodes in the following 
genera: Acontylus, Criconemella, Pseudhalenchus, Afenes 
trata, Cucullity lenchus, Lelenchus, Psilenchus, Aglenchus, 
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Cryphodera, Pterotylenchus, Allotylenchus, Cynipanguina, 
Macrotrophurus, Punctodera, Amplimerlinius, Malenchus, 
Anguina, Discocriconemella, Meloidodera, Radopholus, 
Antarctenchus, Dity lenchus, Meloidoderita, Rhizonema, Ant 
arctylus, Dolichodera, Meloidogyne, Rotylenchulus, Aorolai 
mus, Dolichodorus, Meloinema, Rotylenchus, Aphasmaty 
lenchus, Duotylenchus, Merlinius, Apratylenchoides, 
Miculenchus, Sarisodera, Atalodera, Ecphy adophora, 
Mitranema, Sauerty lenchus, Atetvlenchus, Ecphy adophoroi 
des, Morulaimus, Scutellonema, Atylenchus, Epicharinema, 
Mukazia, Senegalonema, Euty lenchus, Sphaeronema, Bake 
mema, Nacobbodera, Subanguina, Basiria, Filenchus, 
Nacobbus, Sychnotylenchus, Basirienchus, Nagelus, Basiroi 
des, Bellodera, Geocenamus, Neodolichodorus, Thada, 
Belonolaimus, Globodera, Neopsilenchus, Theca vermicula 
tus, Blandicephalanema, Graciliacus, Neothada, Trichotylen 
chus, Boleodorus, Graciliancea, Nothocriconenoides, Triv 
ersus, Brachydorus, Trophonema, Bursadera, Halenchus, 
Ogma, Trophotylenchulus, Helicotylenchus, Paraphelen 
chus, Trophurus, Cacopaurus, Hemicriconenoides, Pararo 
tylenchus, Tvlenchocriconema, Cactodera, Hemicyclio 
phora, Paratrophurus, Tvlenchorhynchus, Caloosia, 
Heterodera, Paratylenchus, Tilenchulus, Cambellenchus, 
Hirschmanniella, Pateracephalanema, Tilenchus, Car 
phodorus, Hoplolaimus, Pleurotylenchus, Tvlodorus, Ceph 
alenchus, Hoplotylus, Polenchus, Clavilenchus, Coslenchus, 
Hylonema, Pratylenchoides, Verutus, Criconema, Pratylen 
chus, Zygotylenchus; and animal parasitic nematodes of the 
following genera: Trichuris, Acylostoma, Necator, Strongy 
loides, Toxocara, Baylisacaris, Trichinella, Draccunculus, 
Filarioidea, Onchocerca, Loa, Dirofilaria, and Anisakis. 
I. RNAi 
RNAi refers to the introduction of homologous double 
stranded RNA (dsRNA) to target a specific gene product, 
resulting in post transcriptional silencing of that gene. This 
phenomena was first reported in Caenorhabditis elegans by 
Guo and Kemphues (Par-1, A gene required for establishing 
polarity in C. elegans embryos, encodes a putative Ser/Thr 
kinase that is asymmetrically distributed, 1995, Cell, 81 (4) 
611-620) and subsequently Fire et al. (Potent and specific 
genetic interference by double-stranded RNA in Caenorhab 
ditis elegans, 1998, Nature 391:806-811) discovered that it is 
the presence of dsRNA, formed from the annealing of sense 
and antisense Strands present in the in vitro RNA preps, that is 
responsible for producing the interfering activity. 
The present invention contemplates the use of RNA inter 
ference (RNAi) to downregulate the expression of genes 
needed for nematode viability and reproduction, thus reduc 
ing nematode infestation of plants. In both plants and ani 
mals, RNAi is mediated by RNA-induced silencing complex 
(RISC), a sequence-specific, multicomponent nuclease that 
destroys messenger RNAS homologous to the silencing trig 
ger. RISC is known to contain short RNAs (approximately 22 
nucleotides) derived from the double-stranded RNA trigger, 
although the protein components of this activity are 
unknown. However, the 22-nucleotide RNA sequences are 
homologous to the target gene that is being Suppressed. Thus, 
the 22-nucleotide sequences appear to serve as guide 
sequences to instruct a multicomponent nuclease, RISC, to 
destroy the specific mRNAs. 
Carthew has reported (Curr. Opin. Cell Biol. 13(2):244 
248 (2001) that eukaryotes silence gene expression in the 
presence of dsRNA homologous to the silenced gene. Bio 
chemical reactions that recapitulate this phenomenon gener 
ate RNA fragments of 21 to 23 nucleotides from the double 
stranded RNA. These stably associate with an RNA 
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endonuclease, and probably serve as a discriminator to select 
mRNAs. Once selected, mRNAs are cleaved at sites 21 to 23 
nucleotides apart. 
In preferred embodiments, the dsRNA used to initiate 
RNAi may be isolated from native source or produced by 
known means, e.g., transcribed from DNA. The promoters 
and vectors described in more detail below are suitable for 
producing dsRNA. RNA is synthesized either in vivo or in 
vitro. In some embodiments, endogenous RNA polymerase 
of the cell may mediate transcription in vivo, or cloned RNA 
polymerase can be used for transcription in vivo or in vitro. In 
other embodiments, the RNA is provided transcription from a 
transgene in Vivo oran expression construct. In some embodi 
ments, the RNA strands are polyadenylated; in other embodi 
ments, the RNA strands are capable of being translated into a 
polypeptide by a cells translational apparatus. In still other 
embodiments, the RNA is chemically or enzymatically syn 
thesized by manual or automated reactions. In further 
embodiments, the RNA is synthesized by a cellular RNA 
polymerase or a bacteriophage RNA polymerase (e.g., T3, 
T7, SP6). If synthesized chemically or by in vitro enzymatic 
synthesis, the RNA may be purified prior to introduction into 
the cell. For example, RNA can be purified from a mixture by 
extraction with a solvent or resin, precipitation, electrophore 
sis, chromatography, or a combination thereof. Alternatively, 
the RNA may be used with no or a minimum of purification to 
avoid losses due to sample processing. In some embodiments, 
the RNA is dried for storage or dissolved in an aqueous 
solution. In other embodiments, the solution contains buffers 
or salts to promote annealing, and/or stabilization of the 
duplex strands. 
In some embodiments, the dsRNA is transcribed from the 
vectors as two separate stands. In other embodiments, the two 
strands of DNA used to form the dsRNA may belong to the 
same or two different duplexes in which they each form with 
a DNA strand of at least partially complementary sequence. 
When the dsRNA is thus-produced, the DNA sequence to be 
transcribed is flanked by two promoters, one controlling the 
transcription of one of the strands, and the other that of the 
complementary Strand. These two promoters may be identical 
or different. In some embodiments, a DNA duplex provided at 
each end with a promoter sequence can directly generate 
RNAs of defined length, and which can join in pairs to form 
a dsRNA. See, e.g., U.S. Pat. No. 5,795,715, incorporated 
herein by reference. RNA duplex formation may be initiated 
either inside or outside the cell. 
Inhibition is sequence-specific in that nucleotide 
sequences corresponding to the duplex region of the RNA are 
targeted for genetic inhibition. RNA molecules containing a 
nucleotide sequence identical to a portion of the target gene 
are preferred for inhibition. RNA sequences with insertions, 
deletions, and single point mutations relative to the target 
sequence have also been found to be effective for inhibition. 
Thus, sequence identity may optimized by sequence com 
parison and alignment algorithms known in the art (see Grib 
skov and Devereux, Sequence Analysis Primer, Stockton 
Press, 1991, and references cited therein) and calculating the 
percent difference between the nucleotide sequences by, for 
example, the Smith-Waterman algorithm as implemented in 
the BESTFIT software program using default parameters 
(e.g., University of Wisconsin Genetic Computing Group). 
Greater than 90% sequence identity, or even 100% sequence 
identity, between the inhibitory RNA and the portion of the 
target gene is preferred. Alternatively, the duplex region of the 
RNA may be defined functionally as a nucleotide sequence 
that is capable of hybridizing with a portion of the target gene 
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transcript. The length of the identical nucleotide sequences 
may be at least 25, 50, 100, 200, 300 or 400 bases. 
There is no upper limit on the length of the dsRNA that can 
be used. For example, the dsRNA can range from about 21 
base pairs (bp) of the gene to the full length of the gene or 
more. In one embodiment, the dsRNA used in the methods of 
the present invention is about 1000 bp in length. In another 
embodiment, the dsRNA is about 500 bp in length. In yet 
another embodiment, the dsRNA is about 22 bp in length. In 
Some preferred embodiments, the sequences that mediate 
RNAi are from about 21 to about 23 nucleotides. That is, the 
isolated RNAs of the present invention mediate degradation 
of the target RNA (e.g., major sperm protein, chitin synthase, 
or RNA polymerase II). 
The double stranded RNA of the present invention need 
only be sufficiently similar to natural RNA that it has the 
ability to mediate RNAi for the target RNA. In one embodi 
ment, the present invention relates to RNA molecules of 
varying lengths that direct cleavage of specific mRNA to 
which their sequence corresponds. It is not necessary that 
there be perfect correspondence of the sequences, but the 
correspondence must be sufficient to enable the RNA to direct 
RNAi cleavage of the target mRNA. In a particular embodi 
ment, the RNA molecules of the present invention comprise a 
3' hydroxyl group. In some embodiments, the amount of 
target RNA (mRNA) is reduced in the cells of the target 
organism (e.g., H. glycines) exposed to target specific double 
Stranded RNA as compared to target organisms that have not 
been exposed to target specific double stranded RNA. 
Accordingly, in Some embodiments, the present invention 
provides isolated RNA molecules (double-stranded or single 
stranded) that are complementary to sequences required for 
nematode viability and/or reproduction. In some embodi 
ments, the RNA molecules utilized mediate RNAi for embry 
onic lethal and sterile genes. Many genes with sterile or 
embryonic lethal RNAi phenotypes have been identified in 
high throughput screens (Fraser, A. G. Kamath, R. S. Zip 
perlen, P., Martinez-Campos, M., Sohrmann, M. and Ahr 
inger, J. (2000). Functional genomic analysis of C. elegans 
chromosome I by systematic RNA interference. Nature 408, 
325-330; Gonczy, P. Echeverri, G., Oegema, K., Coulson, A., 
Jones, S.J., Copley, R. R., Duperon, J. Oegema, J., Brehm, 
M. Cassin, E. et al. (2000). Functional genomic analysis of 
cell division in C. elegans using RNAi of genes on chromo 
some III. Nature 408,331-336; Maeda, I., Kohara, Y., Yama 
moto, M. and Sugimoto, A. (2001). Large-scale analysis of 
gene function in Caenorhabditis elegans by high-throughput 
RNAi. Curr Biol 11, 171-176). Much of this data and all of the 
sequences are available through WormBase (wormbase.org/). 
To date, over 2033 genes have been found to have an embry 
onic lethal RNAi phenotype and over 573 have a sterile RNAi 
phenotype. As described in more detail below and in the 
examples, these sequences may be screened for oral activity 
when expressed in plant tissue. In other embodiments, genes 
from this group that are specific to nematodes are utilized for 
RNAi so as to minimize interactions against endogenous 
proteins of plants, livestock and humans. 
In some embodiments, probes that are specific for a nema 
tode gene of interest are amplified from a DNA sample pre 
pared from C. elegans by using primers designed from C. 
elegans genomic DNA or cDNA. Genes amplified from C. 
elegans DNA are then used as probes for homologous genes 
from a genomic or cDNA libraries prepared from the nema 
tode of interest (e.g., H. glycines). In other embodiments, 
degenerate primers based on the C. elegans sequences are 
utilized to amplify the gene of interest from a library derived 
from the nematode of interest. These genes are then inserted 
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into an expression vector so that a nematode double stranded 
RNA corresponding to the gene of interest is produced when 
the vector is used to transfect a plant. 
Accordingly, in Some embodiments, the present invention 
utilizes RNAi genes encoding dsRNA sequences that target 
nematode genes identified as having embryonic lethal or ster 
ile RNAi phenotypes as identified by feeding nematodes 
dsRNA. The coding sequences for the target RNAs are avail 
able in public databases, including Wormbase (wormbase 
.org). In still further embodiments, the genes utilized for 
RNAi are selected from the group consisting of major sperm 
protein, chitin synthase, and RNA polymerase II. The meth 
ods and compositions of the present invention have been 
exemplified for the control of H. glycines. However, it will be 
recognized that these materials and methods can be used the 
control of other nematodes. Accordingly the present inven 
tion provides the sequences for H. glycines major sperm 
protein (e.g., SEQ ID NO:1), chitin synthase (e.g., SEQ ID 
NO:18), and RNA polymerase II (e.g., SEQ ID NO:9). As 
described above, the entire coding sequence of the genes can 
be used to make dsRNA for RNAi, or, alternatively, subse 
quences can be utilized. The following table presents other 
suitable subsequences for use in RNAi. Both these sequences 
and their complements are expressed from vectors as 
described herein to form double stranded RNA molecules. 
TABLE 1. 
Sequences for RNAi 
Major sperm protein subsequences 
SEQ ID NO: 25 CGGGGTCGAAGGCGTCNCAGAANACGGCCAC 
GTTGACAGATTCCTTTGGGCCGANCACTCCG 
TCCGGCGGGTTCATGTTGATNCGCTTCGGTTTG 
CGTGGTGTCGGCTGGGTCCGGTGT 
GTTGGTCCACTCCGC 
GGCACGTTGGTCCACGCCACG 
GTCACACGGTCGTCCTTGGTGTCCTCGCTGC 
GGCGTCNCAGAANACGGCCAC 
GTTGACAGATTCCTTTGGGCCGANCACTCCG 
GGGCGGTTCCGGCACGTTGGTCCACGCCACG 
GTCACACGGTCGTCCTTGGTGTCCTCGCTGC 
SEQ 
SEQ 
ID 
ID 
NO: 
NO: 
26 
27 
SEQ ID NO:28 
SEQ ID NO: 29 
SEQ ID NO:30 
RNA polymerase II subsequences 
SEO ID NO:31 AATCTGTCAACGTGGCCGTNTTCTGNGACGCC 
TTCGACCCCGGCAGCGAGGACACCAAGGACGA 
CCGTGTGACCGTGGCGTGGACCAACGTGCCGG 
AACCGCCCGGCGCCGCCGCCGCCGCGGAGTGG 
ACCAACACACCGGACCCAGCCGACACCACGTT 
CAAG 
GGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGA 
AGGCGTCNCAGAANACGGCCACGTTGACAGATT 
CCTTTGGGCCGANCACTCCGTCCGGCGGGTTCA 
TGTTGATNCGCTTCGGTTTG 
TTGAACGTGGTGTCGGCTGGGTCCGGTGTGTT 
GGTCCACTCCGCGGCGGCGGCGGCGCCGGGCG 
GTTCCGGCACGTTGGTCCACGCCACGGTCACAC 
GGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGA 
GGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGA 
AGGCGTCNCAGAANACGGCCACGTTGACAGATT 
TTCAAGACCACCAAACCGAAGCGNATCAACAT 
GAACCCGCCGGACGGAGTGNTCGGCCCAAAGG 
AATCTGTCAACGTGGCCGTNTTCTGNGACGCC 
TTCGACCCCGGCAGCGAGGACACCAAGGACGA 
CCGTGTGACCGTGGCGTGGACCAACGTGCCGG 
AACCGCCCGGCGCCGCCGCCGCCGCGGAGTGG 
ACCAACACACCGGACCCAGCCGACACCACGTT 
ATCATGTCCATGTTGAGGTGACGAAGCATCCTTCCAT 
CAGACGTTGTACTCGATCGGCAAGTTCTTGCGGC 
GCACCATCCCGTCTCCCTGGAACCA 
SEQ ID NO:32 
SEQ ID NO:33 
SEQ ID NO:34 
SEO ID NO:35 
SEQ ID NO:36 
SEO ID NO:37 
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TABLE 1 - continued 
Sequences for RNAi 
Chitin synthase sequences 
SEO ID NO:38 TGGTTTGGTACCAAAAGTTCGAGTACGCAATCGC 
CCATTGGTTCCAAAAG 
GCTGCTGAGCATGTGTTCGGCTGTGTTTTGTGTGC 
CCCCGGTAGCTTCTC 
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGT 
GATGCACAAATACA 
CCAAAANTGCCTCCGAACCNACGACNATTTTGTTC 
AGTATGATCAAGGCGAAGACCCGATGGA 
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGT 
GATGCACAAATACACCAAAANTGCCTCCGAACCN 
ACGACNATTTTGTTCAGTATGATCAAGGCG 
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGT 
GATGCACAAATACACCAAAANTGCCTCCGAACCNA 
CGACNATTTTGTTCAGTATGATCAAGGCG 
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGTG 
ATGCACAAATACACCAAA. 
SEO ID NO:39 
SEO ID NO: 40 
SEO ID NO: 41 
SEO ID NO: 42 
SEO ID NO: 43 
SEO ID NO: 44 
Additionally, homologous sequences from other nema 
todes may be utilized for targeting the corresponding species 
of nematode. For example, a number of homologous Major 
sperm protein genes are known, including those identified by 
the following GenBank Accession numbers: GI403083, 
GI403087, GI17535306, GI159665, GI1373354, 
GI1373307, GI159897, GI12055908, and GI12055882 
among others. Such sequences can be conveniently identified 
by conducting BLASTN of BLASTP searches of GenBank as 
appropriate. 
Other genes that are useful for targeting include those 
described in Kamath et al., Effectiveness of specific RNA 
mediated interference through ingested double-stranded 
RNA in Caenorhabditis elegans. Genome Biology, 201):re 
search0002.1-0002.10 (2000). These genes are identified in 
the following Table: 
TABLE 2 
Gene(s) Feeding phenotype Gene information 
KO4G2.8a. Unc, Bmd, Lvl apr-1 (APC-related) 
F18C12.2a. Emb, Unc, Mlt, Bmd DNA-J domain 
ZK265.5, 6* Gro G-protein-coupled 
receptorfunknown function 
TO1 G9.4 Emb, Gro, Clr kup-2 (unknown function) 
TO1 G9.5 Emb mei-1 (meiotic spindle formation) 
TO1 G9.6a Emb, Gro, Pvl kin-10 (CKII-beta subunit) 
F52B5.6 Emb, Ste Ribosomal protein L25 
T19A6.2a. Gro Ynr053p-like protein 
D1081.2 Unc, Prz MADS domain 
D1081.8 Emb Myb-like DNA-binding 
domain 
KO2B12.1 Unc, Mlt ceh-6 (POU homeodomain 
protein) 
KO2B12.3 Ste, Gro WD domains 
KO2B12.8 Him Unknown function 
Gpb-1 
gpb-1 Mt. Identity of corresponding 
gene under review 
bar-1 Mt. required for establishing 
polarity 
bar-2 Mt. required for blastomere 
asymmetry 
par-3 Mt. control of cleavage spindle 
orientation 
par-6 Mt. involved in the 
establishment of asymmetry 
cyk-1 Mt. required for cytokinesis 
skin-1 Mt. required for mitotic 
spindle orientation 
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TABLE 2-continued 
Gene(s) Feeding phenotype Gene information 
dnc-1 Mt required for mitotic spindle 
orientation 
bir-1 Mt inhibitor of apoptosis 
protein (IAP) homologue 
pal-1 Mt required to specify the 
Somatic identity of one 
posterior blastomere in the 
4 cell embryo 
dif-1 Mt Mitochondrial Transporters 
plk-1 Mt Polo-like kinase PLK-1 is 
required for nuclear 
envelope breakdown and 
the completion of meiosis 
dhc-1 Mtl, Emb Dynein Heavy Chain 
mex-3 Mt regulates blastomere 
identity 
Bmd, body morphology defect; Clr, clear; Emb, embryonic lethal; Gro, slow growth; Him, 
high incidence ofmales;Lwl, larvallethal (death at any larval stage); Milt, molting defect (old 
cuticle remains attached); Prz, paralyzed; Pwl, protruding vulva; Ste, sterile; Unc, uncoor 
dinated; Mtl, maternal lethal. 
II. Transgenic Plants 
In some embodiments, the present invention provides 
transgenic plants that express dsRNA molecules that corre 
spond to target molecules in desired nematode species. It is 
contemplated that nematodes feeding on the transgenic plants 
ingest the dsRNA molecules, which in turn decrease the abun 
dance of target RNA within the nematode species. By target 
ing genes that are required for fertility or fitness of the nema 
tode, nematode growth and reproduction is reduced thus 
reducing nematode induced plant damage (e.g., root cysts). 
A heterologous gene encoding a RNAi gene of the present 
invention, which includes variants of the RNAi gene, includes 
any suitable sequence that encodes an double stranded mol 
ecule specific for a nematode target RNA. Preferably, the 
heterologous gene is provided within an expression vector 
Such that transformation with the vector results in expression 
of the double stranded RNA molecule; suitable vectors are 
described below. 
In yet other embodiments of the present invention, a trans 
genic plant comprises a heterologous gene encoding a RNAi 
gene of the present invention operably linked to an inducible 
promoter, and is grown either in the presence of the an induc 
ing agent, or is grown and then exposed to an inducing agent. 
In still other embodiments of the present invention, a trans 
genic plant comprises a heterologous gene encoding a RNAi 
gene of the present invention operably linked to a promoter 
which is either tissue specific or developmentally specific, 
and is grown to the point at which the tissue is developed or 
the developmental stage at which the developmentally-spe 
cific promoter is activated. Such promoters include seed and 
root specific promoters. In still other embodiments of the 
present invention, the transgenic plant comprises a RNAi 
gene of the present invention operably linked to constitutive 
promoter. In further embodiments, the transgenic plants of 
the present invention express at least one double stranded 
RNA molecule at a level sufficient to reduce the proliferation 
of nematodes as compared to the proliferation of nematodes 
observed in a nontransgenic plant. 
1. Plants 
The methods of the present invention are not limited to any 
particular plant. Indeed, a variety of plants are contemplated, 
including but not limited to soybean, wheat, oats, milo, Sor 
ghum, cotton, tomato, potato, tobacco, pepper, rice, corn, 
barley, Brassica, Arabidopsis, Sunflower, poplar, pineapple, 
banana, turfgrass, and pine. Many commercial cultivars can 
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be transformed with heterologous genes. In cases where that 
is not possible, non-commercial cultivars of plants can be 
transformed, and the trait for expression of the RNAi gene of 
the present invention moved to commercial cultivars by 
breeding techniques well-known in the art. 
2. Vectors 
The methods of the present invention contemplate the use 
of at least one heterologous gene encoding a RNAi gene of the 
present invention. Heterologous genes intended for expres 
sion in plants are first assembled in expression cassettes com 
prising a promoter. Methods which are well known to those 
skilled in the art may be used to construct expression vectors 
containing a heterologous gene and appropriate transcrip 
tional and translational control elements. These methods 
include invitro recombinant DNA techniques, synthetic tech 
niques, and in vivo genetic recombination. Such techniques 
are widely described in the art (See e.g., Sambrook. et al. 
(1989) Molecular Cloning, A Laboratory Manual, Cold 
Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et 
al. (1989) Current Protocols in Molecular Biology, John 
Wiley & Sons, New York, N.Y). 
In general, these vectors comprise a nucleic acid sequence 
of the invention encoding a RNAi gene of the present inven 
tion (as described above) operably linked to a promoter and 
other regulatory sequences (e.g., enhancers, polyadenylation 
signals, etc.) required for expression in a plant. 
Promoters include but are not limited to constitutive pro 
moters, tissue-, organ-, and developmentally-specific pro 
moters, and inducible promoters. Examples of promoters 
include but are not limited to: constitutive promoter 35S of 
cauliflower mosaic virus; a wound-inducible promoter from 
tomato, leucine amino peptidase (“LAP Chao et al. (1999) 
Plant Physiol 120: 979-992); a chemically-inducible pro 
moter from tobacco, Pathogenesis-Related 1 (PR1) (induced 
by salicylic acid and BTH (benzothiadiazole-7-carbothioic 
acid S-methyl ester)); a tomato proteinase inhibitor II pro 
moter (PIN2) or LAP promoter (both inducible with methyl jasmonate); a heat shock promoter (U.S. Pat. No. 5,187.267); 
a tetracycline-inducible promoter (U.S. Pat. No. 5,057,422); 
and seed-specific promoters, such as those for seed storage 
proteins (e.g., phaseolin, napin, oleosin, and a promoter for 
soybean beta conglycin (Beachy et al. (1985) EMBO J. 4: 
3047-3053)). In some preferred embodiments, the promoter 
is a phaseolin promoter. All references cited herein are incor 
porated in their entirety. 
The expression cassettes may further comprise any 
sequences required for expression of mRNA. Such sequences 
include, but are not limited to transcription terminators, 
enhancers such as introns, viral sequences, and sequences 
intended for the targeting of the gene product to specific 
organelles and cell compartments. 
A variety of transcriptional terminators are available for 
use in expression of sequences using the promoters of the 
present invention. Transcriptional terminators are responsible 
for the termination of transcription beyond the transcript and 
its correct polyadenylation. Appropriate transcriptional ter 
minators and those which are known to function in plants 
include, but are not limited to, the CaMV 35S terminator, the 
tml terminator, the pea rbcS E9 terminator, and the nopaline 
and octopine synthase terminator (See e.g., Odelletal. (1985) 
Nature 313:810; Rosenberg et al. (1987) Gene, 56:125; 
Guerineau et al. (1991) Mol. Gen. Genet., 262:141; Proudfoot 
(1991) Cell, 64:671; Sanfacon et al. Genes Dev. 5:141; 
Mogen et al. (1990) Plant Cell, 2:1261; Munroe et al. (1990) 
Gene, 91:151; Ballad et al. (1989) Nucleic Acids Res. 
17:7891; Joshi et al. (1987) Nucleic Acid Res., 15:9627). 
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In addition, in some embodiments, constructs for expres 
sion of the gene of interest include one or more of sequences 
found to enhance gene expression from within the transcrip 
tional unit. These sequences can be used in conjunction with 
the nucleic acid sequence of interest to increase expression in 
plants. Various intron sequences have been shown to enhance 
expression, particularly in monocotyledonous cells. For 
example, the introns of the maize Adh1 gene have been found 
to significantly enhance the expression of the wild-type gene 
under its cognate promoter when introduced into maize cells 
(Calais et al. (1987) Genes Develop. 1: 1183). Intron 
sequences have been routinely incorporated into plant trans 
formation vectors, typically within the non-translated leader. 
In some embodiments of the present invention, the con 
struct for expression of the nucleic acid sequence of interest 
also includes a regulator Such as a nuclear localization signal 
(Calderone et al. (1984) Cell 39:499; Lassoer et al. (1991) 
Plant Molecular Biology 17:229), a plant translational con 
sensus sequence (Joshi (1987) Nucleic Acids Research 
15:6643), an intron (Luehrsen and Walbot (1991) Mol. Gen. 
Genet. 225:81), and the like, operably linked to the nucleic 
acid sequence encoding ADS. 
In preparing a construct comprising a nucleic acid 
sequence encoding a RNAi gene of the present invention, 
various DNA fragments can be manipulated, so as to provide 
for the DNA sequences in the desired orientation (e.g., sense 
orantisense) orientation. For example, adapters or linkers can 
be employed to join the DNA fragments or other manipula 
tions can be used to provide for convenient restriction sites, 
removal of superfluous DNA, removal of restriction sites, or 
the like. For this purpose, in vitro mutagenesis, primer repair, 
restriction, annealing, resection, ligation, or the like is pref 
erably employed, where insertions, deletions or substitutions 
(e.g., transitions and transversions) are involved. 
Numerous transformation vectors are available for plant 
transformation. The selection of a vector for use will depend 
upon the preferred transformation technique and the target 
species for transformation. For certain target species, differ 
ent antibiotic or herbicide selection markers are preferred. 
Selection markers used routinely in transformation include 
the nptII gene which confers resistance to kanamycin and 
related antibiotics (Messing and Vierra (1982) Gene 19: 259; 
Bevan et al. (1983) Nature 304:184), the bar gene which 
confers resistance to the herbicide phosphinothricin (White et 
al. (1990) Nucl Acids Res. 18:1062: Spencer et al. (1990) 
Theor. Appl. Genet. 79:625), the hph gene which confers 
resistance to the antibiotic hygromycin (Blochlinger and 
Diggelmann (1984) Mol. Cell. Biol. 4:2929), and the dhfr 
gene, which confers resistance to methotrexate (Bourouis et 
al. (1983) EMBO.J., 2:1099). 
In some preferred embodiments, the vector is adapted for 
use in an Agrobacterium mediated transfection process (See 
e.g., U.S. Pat. Nos. 5,981,839; 6,051,757; 5,981,840; 5,824, 
877; and 4,940,838; all of which are incorporated herein by 
reference). Construction of recombinant Ti and Ri plasmids 
in general follows methods typically used with the more 
common bacterial vectors, such as pBR322. Additional use 
can be made of accessory genetic elements sometimes found 
with the native plasmids and sometimes constructed from 
foreign sequences. These may include but are not limited to 
structural genes for antibiotic resistance as selection genes. 
There are two systems of recombinant Ti and Ri plasmid 
vector systems now in use. The first system is called the 
"cointegrate” system. In this system, the shuttle vector con 
taining the gene of interest is inserted by genetic recombina 
tion into a non-oncogenic Tiplasmid that contains both the 
cis-acting and trans-acting elements required for plant trans 
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formation as, for example, in the pMLJ1 shuttle vector and 
the non-oncogenic Tiplasmid pGV3850. The second system 
is called the “binary” system in which two plasmids are used; 
the gene of interest is inserted into a shuttle vector containing 
the cisacting elements required for plant transformation. The 
other necessary functions are provided in trans by the non 
oncogenic Tiplasmid as exemplified by the pBIN19 shuttle 
vector and the non-oncogenic Tiplasmid PAL4404. Some of 
these vectors are commercially available. 
In other embodiments of the invention, the nucleic acid 
sequence of interest is targeted to a particular locus on the 
plant genome. Site-directed integration of the nucleic acid 
sequence of interest into the plant cell genome may be 
achieved by, for example, homologous recombination using 
Agrobacterium-derived sequences. Generally, plant cells are 
incubated with a strain of Agrobacterium which contains a 
targeting vector in which sequences that are homologous to a 
DNA sequence inside the target locus are flanked by Agro 
bacterium transfer-DNA (T-DNA) sequences, as previously 
described (U.S. Pat. No. 5,501,967). One of skill in the art 
knows that homologous recombination may be achieved 
using targeting vectors which contain sequences that are 
homologous to any part of the targeted plant gene, whether 
belonging to the regulatory elements of the gene, or the cod 
ing regions of the gene. Homologous recombination may be 
achieved at any region of a plant gene So long as the nucleic 
acid sequence of regions flanking the site to be targeted is 
known. 
In yet other embodiments, the nucleic acids of the present 
invention are utilized to construct vectors derived from plant 
(+)RNA viruses (e.g., brome mosaic virus, tobacco mosaic 
virus, alfalfa mosaic virus, cucumber mosaic virus, tomato 
mosaic virus, and combinations and hybrids thereof). Gener 
ally, the inserted ADS polynucleotide of the present invention 
can be expressed from these vectors as a fusion protein (e.g., 
coat protein fusion protein) or from its own Subgenomic 
promoter or other promoter. Methods for the construction and 
use of such viruses are described in U.S. Pat. Nos. 5,846,795; 
5,500,360; 5,173,410; 5,965,794; 5,977,438; and 5,866,785, 
all of which are incorporated herein by reference. 
In some embodiments of the present invention the nucleic 
acid sequence of interest is introduced directly into a plant. 
One vector useful for direct gene transfer techniques in com 
bination with selection by the herbicide Basta (or phosphino 
thricin) is a modified version of the plasmid pCIB246, with a 
CaMV 35S promoter in operational fusion to the E. coli GUS 
gene and the CaMV 35S transcriptional terminator (WO 
93/07278). 
3. Transformation Techniques 
Once a nucleic acid sequence encoding an ADS of the 
present invention is operatively linked to an appropriate pro 
moter and inserted into a suitable vector for the particular 
transformation technique utilized (e.g., one of the vectors 
described above), the recombinant DNA described above can 
be introduced into the plant cell in a number of art-recognized 
ways. Those skilled in the art will appreciate that the choice of 
method might depend on the type of plant targeted for trans 
formation. In some embodiments, the vector is maintained 
episomally. In other embodiments, the vector is integrated 
into the genome. 
In some embodiments, the vector is introduced through 
ballistic particle acceleration using devices (e.g., available 
from Agracetus, Inc., Madison, Wis. and Dupont, Inc., Wilm 
ington, Del.). (See e.g., U.S. Pat. No. 4,945.050; and McCabe 
etal. (1988) Biotechnology 6:923). See also, Weissinger et al. 
(1988) Annual Rev. Genet. 22:421; Sanford et al. (1987) 
Particulate Science and Technology, 5:27 (onion); Svab et al. 
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(1990) Proc. Natl. Acad. Sci. USA, 87:8526 (tobacco chlo 
roplast); Christou et al. (1988) Plant Physiol. 87:671 (soy 
bean); McCabe et al. (1988) Bio/Technology 6:923 (soy 
bean): Kleinet al. (1988) Proc. Natl. Acad. Sci. USA,85:43.05 
(maize): Klein et al. (1988) Bio/Technology, 6:559 (maize): 
Klein et al. (1988) Plant Physiol.,91:4404 (maize): Fromm et 
al. (1990) Bio/Technology, 8:833; and Gordon-Kamm et al. 
(1990) Plant Cell. 2:603 (maize): Koziel et al. (1993) Bio 
technology, 11:194 (maize); Hill et al. (1995) Euphytica, 
85:119 and Koziel et al. (1996) Annals of the New York 
Academy of Sciences 792: 164; Shimamoto et al. (1989) 
Nature 338: 274 (rice); Christou et al. (1991) Biotechnology, 
9:957 (rice); Datta et al. (1990) Bio/Technology 8:736 (rice); 
European Patent Application EP 0332 581 (orchardgrass and 
other Pooideae); Vasil et al. (1993) Biotechnology, 11: 1553 
(wheat); Weeks et al. (1993) Plant Physiol., 102: 1077 
(wheat); Wan et al. (1994) Plant Physiol. 104:37 (barley); 
Jahne et al. (1994) Theor. Appl. Genet. 89:525 (barley); 
Knudsen and Muller (1991) Planta, 185:330 (barley); 
Umbecket al. (1987) Bio/Technology 5: 263 (cotton); Casas 
etal. (1993) Proc. Natl. Acad. Sci. USA90:11212 (sorghum); 
Somers et al. (1992) Bio/Technology 10:1589 (oat); Torbert 
et al. (1995) Plant Cell Reports, 14:635 (oat); Weeks et al. 
(1993) Plant Physiol., 102:1077 (wheat); Chang et al., WO 
94/13822 (wheat) and Nehra et al. (1994) The Plant Journal, 
5:285 (wheat). 
In other embodiments, direct transformation in the plastid 
genome is used to introduce the vector into the plant cell (See 
e.g., U.S. Pat. Nos. 5,451,513; 5,545,817: 5,545,818; PCT 
application WO95/16783). The basic technique for chloro 
plast transformation involves introducing regions of cloned 
plastid DNA flanking a selectable marker together with the 
nucleic acid encoding the RNA sequences of interest into a 
Suitable target tissue (e.g., using biolistics or protoplast trans 
formation with calcium chloride or PEG). The 1 to 1.5 kb 
flanking regions, termed targeting sequences, facilitate 
homologous recombination with the plastid genome and thus 
allow the replacement or modification of specific regions of 
the plastome. Initially, point mutations in the chloroplast 16S 
rRNA and rps 12 genes conferring resistance to spectinomy 
cin and/or streptomycin are utilized as selectable markers for 
transformation (Svab et al. (1990) PNAS, 87:8526; Staub and 
Maliga, (1992) Plant Cell, 4:39). The presence of cloning 
sites between these markers allowed creation of a plastid 
targeting vector introduction of foreign DNA molecules 
(Staub and Maliga (1993) EMBO J., 12:601). Substantial 
increases in transformation frequency are obtained by 
replacement of the recessive rRNA or r-protein antibiotic 
resistance genes with a dominant selectable marker, the bac 
terial aadA gene encoding the spectinomycin-detoxifying 
enzyme aminoglycoside-3'-adenyltransferase (Svab and 
Maliga (1993) PNAS,90:913). Other selectable markers use 
ful for plastid transformation are known in the art and encom 
passed within the scope of the present invention. Plants 
homoplasmic for plastid genomes containing the two nucleic 
acid sequences separated by a promoter of the present inven 
tion are obtained, and are preferentially capable of high 
expression of the RNAs encoded by the DNA molecule. 
In other embodiments, vectors useful in the practice of the 
present invention are microinjected directly into plant cells by 
use of micropipettes to mechanically transfer the recombi 
nant DNA (Crossway (1985) Mol. Gen. Genet, 202:179). In 
still other embodiments, the vector is transferred into the 
plant cell by using polyethylene glycol (Krens et al. (1982) 
Nature, 296:72; Crossway et al. (1986) BioTechniques, 
4:320): fusion of protoplasts with other entities, either mini 
cells, cells, lysosomes or other fusible lipid-surfaced bodies 
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(Fraley et al. (1982) Proc. Natl. Acad. Sci., USA, 79:1859); 
protoplast transformation (EPO 292.435); direct gene transfer 
(Paszkowski et al. (1984) EMBO J., 3:2717: Hayashimoto et 
al. (1990) Plant Physiol. 93:857). 
In still further embodiments, the vector may also be intro 
duced into the plant cells by electroporation (Fromm, et al. 
(1985) Proc. Natl Acad. Sci. USA 82:5824; Riggs et al. 
(1986) Proc. Natl. Acad. Sci. USA 83:5602). In this tech 
nique, plant protoplasts are electroporated in the presence of 
plasmids containing the gene construct. Electrical impulses 
of high field strength reversibly permeabilize biomembranes 
allowing the introduction of the plasmids. Electroporated 
plant protoplasts reform the cell wall, divide, and form plant 
callus. 
In addition to direct transformation, in some embodiments, 
the vectors comprising a nucleic acid sequence encoding a 
RNAi gene of the present invention are transferred using 
Agrobacterium-mediated transformation (Hinchee et al. 
(1988) Biotechnology, 6:915: Ishida et al. (1996) Nature Bio 
technology 14:745). Agrobacterium is a representative genus 
of the gram-negative family Rhizobiaceae. Its species are 
responsible for plant tumors such as crown gall and hairy root 
disease. In the dedifferentiated tissue characteristic of the 
tumors, amino acid derivatives known as opines are produced 
and catabolized. The bacterial genes responsible for expres 
sion of opines area convenient source of control elements for 
chimeric expression cassettes. Heterologous genetic 
sequences (e.g., nucleic acid sequences operatively linked to 
a promoter of the present invention), can be introduced into 
appropriate plant cells, by means of the Tiplasmid of Agro 
bacterium tumefaciens. The Tiplasmid is transmitted to plant 
cells on infection by Agrobacterium tumefaciens, and is sta 
bly integrated into the plant genome (Schell (1987) Science, 
237: 1176). Species which are susceptible infection by Agro 
bacterium may be transformed in vitro. Alternatively, plants 
may be transformed in vivo. Such as by transformation of a 
whole plant by Agrobacteria infiltration of adult plants, as in 
a “floral dip” method (Bechtold N, Ellis J. Pelletier G (1993) 
Cr. Acad. Sci. III-Vie 316: 1194-1199). 
4. Regeneration 
After selecting for transformed plant material that can 
express the heterologous gene encoding a RNAi gene of the 
present invention, whole plants are regenerated. Plant regen 
eration from cultured protoplasts is described in Evans et al. 
(1983) Handbook of Plant Cell Cultures, Vol. 1: (MacMillan 
Publishing Co. New York); and Vasil I. R. (ed.), Cell Culture 
and Somatic Cell Genetics of Plants, Acad. Press, Orlando, 
Vol. I (1984), and Vol. III (1986). It is known that many plants 
can be regenerated from cultured cells or tissues, including 
but not limited to all major species of Sugarcane, Sugar beet, 
cotton, fruit and other trees, legumes and vegetables, and 
monocots (e.g., the plants described above). Means for regen 
eration vary from species to species of plants, but generally a 
Suspension of transformed protoplasts containing copies of 
the heterologous gene is first provided. Callus tissue is 
formed and shoots may be induced from callus and Subse 
quently rooted. 
Alternatively, embryo formation can be induced from the 
protoplast Suspension. These embryos germinate and form 
mature plants. The culture media will generally contain vari 
ous amino acids and hormones, such as auxin and cytokinins. 
Shoots and roots normally develop simultaneously. Efficient 
regeneration will depend on the medium, on the genotype, 
and on the history of the culture. The reproducibility of regen 
eration depends on the control of these variables. 
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5. Generation of Transgenic Lines 
Transgenic lines are established from transgenic plants by 
tissue culture propagation. The presence of nucleic acid 
sequences encoding a RNAi gene of the present invention 
(including mutants or variants thereof) may be transferred to 
related varieties by traditional plant breeding techniques. 
These transgenic lines are then utilized for evaluation of oil 
production and other agronomic traits. 
III. Animal Feeds Containing dsRNA Molecules 
The present invention provides animals feeds comprising 
dsRNA molecules derived from plants. In some embodi 
ments, the dsRNA molecules are present in seeds and seed 
products derived from the transgenic plants described above. 
It is contemplated that providing feed containing dsRNA to 
animals results in a decrease in nematode infestation of the 
animals. Suitable methods for formulating feed are well 
known in the art. Feeds for a variety of animals may be 
formulated, including but not limited to, pigs, cattle, sheep, 
chickens, turkeys and other poultry, fish, horses, dogs, cats, 
and rabbits. 
In other embodiments, the transgenic plant material is 
encapsulated. For example, in Some embodiments, tablets or 
capsules of the present invention are coated with an enteric 
coating which dissolves at a pH of about 6.0 to 7.0. A suitable 
enteric coating which dissolves in the Small intestine but not 
in the stomach is cellulose acetate phthalate. Further details 
on techniques for formulation for and administration and 
administration may be found in the latest edition of Reming 
ton's Pharmaceutical Sciences (Maack Publishing Co., Eas 
ton, Pa.). 
In further embodiments, the present invention provides 
pharamaceutical compositions comprising transgenic plant 
material derived from transgenic plants expressing a nema 
tode double stranded RNA. In some embodiments, the phar 
maceutical compositions of the present invention can be for 
mulated using pharmaceutically acceptable carriers well 
known in the art in dosages Suitable for oral administration. 
Such carriers enable the pharmaceutical compositions to be 
formulated as tablets, pills, capsules, liquids, gels, syrups, 
slurries, Suspensions and the like, for oral or nasal ingestion 
by a subject to be treated. 
Pharmaceutical compositions suitable for use in the 
present invention include compositions wherein the active 
ingredients are contained in an effective amount to achieve 
the intended purpose. Determination of effective amounts is 
well within the capability of those skilled in the art, especially 
in light of the disclosure provided herein. In some embodi 
ments, a therapeutically effective dose refers to that amount 
of plant material that ameliorates symptoms of the disease 
state (i.e., nematode infestation). Toxicity and therapeutic 
efficacy of Such compounds can be determined by standard 
pharmaceutical procedures in in vitro models or experimental 
animals, e.g., for determining the LDso (the dose lethal to 
50% of the population)and the EDs (the dose therapeutically 
effective in 50% of the population). The dose ratio between 
toxic and therapeutic effects is the therapeutic index, and it 
can be expressed as the ratio LDso/EDso. Compounds that 
exhibit large therapeutic indices are preferred. The data 
obtained from these cell culture assays and additional animal 
studies can be used in formulating a range of dosage for 
human use. The dosage of Such compounds lies preferably 
within a range of circulating concentrations that include the 
EDs with little or no toxicity. The dosage varies within this 
range depending upon the dosage form employed, sensitivity 
of the patient, and the route of administration. 
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In addition to the active ingredients these pharmaceutical 
compositions may contain Suitable pharmaceutically accept 
able carriers comprising excipients and auxiliaries that facili 
tate processing of the active compounds into preparations that 
can be used pharmaceutically. The preparations formulated 
for oral administration may be in the form of tablets, dragees, 
capsules, or solutions. 
The pharmaceutical compositions of the present invention 
may be manufactured in a manner that is itself known (e.g., by 
means of conventional mixing, dissolving, granulating, dra 
gee-making, levigating, emulsifying, encapsulating, entrap 
ping or lyophilizing processes). 
Pharmaceutical formulations for parenteral administration 
include aqueous solutions of the active compounds in water 
soluble form. Additionally, Suspensions of the active com 
pounds may be prepared as appropriate oily injection Suspen 
sions. Suitable lipophilic solvents or vehicles include fatty 
oils such as sesame oil, or synthetic fatty acid esters. Such as 
ethyl oleate or triglycerides, or liposomes. Aqueous injection 
Suspensions may contain Substances that increase the viscos 
ity of the Suspension, such as sodium carboxymethyl cellu 
lose, Sorbitol, or dextran. Optionally, the Suspension may also 
contain Suitable stabilizers or agents that increase the Solu 
bility of the compounds to allow for the preparation of highly 
concentrated Solutions. 
Pharmaceutical preparations for oral use can be obtained 
by combining the active compounds with Solid excipient, 
optionally grinding a resulting mixture, and processing the 
mixture of granules, after adding Suitable auxiliaries, if 
desired, to obtain tablets or dragee cores. Suitable excipients 
are carbohydrate or protein fillers such as Sugars, including 
lactose, sucrose, mannitol, or sorbitol; starch from corn, 
wheat, rice, potato, etc.; cellulose Such as methyl cellulose, 
hydroxypropylmethyl-cellulose, or sodium carboxymethyl 
cellulose; and gums including arabic and tragacanth; and 
proteins such as gelatin and collagen. If desired, disintegrat 
ing or solubilizing agents may be added, such as the cross 
linked polyvinyl pyrrolidone, agar, alginic acid or a salt 
thereof such as Sodium alginate. 
Dragee cores are provided with Suitable coatings Such as 
concentrated Sugar Solutions, which may also contain gum 
arabic, talc, polyvinylpyrrolidone, carbopolgel, polyethylene 
glycol, and/or titanium dioxide, lacquer Solutions, and Suit 
able organic solvents or solvent mixtures. Dyestuffs or pig 
ments may be added to the tablets or dragee coatings for 
product identification or to characterize the quantity of active 
compound, (i.e., dosage). 
Pharmaceutical preparations that can be used orally 
include push-fit capsules made of gelatin, as well as Soft, 
sealed capsules made of gelatin and a coating Such as glycerol 
or Sorbitol. The push-fit capsules can contain the active ingre 
dients mixed with a filler or binders such as lactose or 
starches, lubricants such as talc or magnesium Stearate, and, 
optionally, stabilizers. In soft capsules, the active compounds 
may be dissolved or Suspended in Suitable liquids, such as 
fatty oils, liquid paraffin, or liquid polyethylene glycol with or 
without stabilizers. 
EXPERIMENTAL 
The following examples are provided in order to demon 
strate and further illustrate certain preferred embodiments 
and aspects of the present invention and are not to be con 
Strued as limiting the scope thereof. 
In the experimental disclosures which follow, the follow 
ing abbreviations apply: N (normal); M (molar); mM (milli 
molar); LM (micromolar); mol (moles); mmol (millimoles); 
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umol (micromoles); nmol (nanomoles); pmol (picomoles); g (grams); mg (milligrams); Lug (micrograms), ng (nanograms); 
1 or L (liters); ml (milliliters); ul (microliters); cm (centime 
ters); mm (millimeters); um (micrometers); nm (nanom 
eters); C. (degrees Centigrade). 
Example 1 
Construction of Major Sperm Protein RNAi Gene 
This Example describes the construction of the expression 
construct for MSP dsRNA for use in RNAi. Conserved 
regions of the MSP gene for various nematodes were found 
using “Block Maker. Degenerate primers were synthesized 
and apartial gene fragment was amplified from SCN genomic 
DNA. The fragment was cloned into pGEM-T Easy vector, 
sequenced, and used for a BLAST search in GenBank. The 
cloned sequence showed homology with MSP genes from 
other nematodes. The fragment was used to probe a cDNA 
library made from J2juveniles. 
A subclone was identified in a SCNJ2 cDNA lambda 
library and sequenced. This sequence is presented in FIG.1 as 
SEQID NO:1. A T7 primer (5'gtaata cgactic actataggg c 3'; 
SEQID NO:2) and MSP specific primer (5' cca tpgctgcag 
gcc ttcaag acc ac 3'; SEQ ID NO:3: reverse compliment 
identified by double underline in FIG.1) were used to amplify 
an approximately 600 base pair fragment of MSP. The MSP 
specific primer (SEQ ID NO:3) was designed to introduce 
NcoI (CCATGG) and PstI (CTGCA'G) sites at the 5' end of 
the amplified product. The resulting amplified fragment was 
then subcloned into pGEM-T. The subcloned sequence was 
then excised from the vector by digestion with BamHI and 
EcoRI to provide SEQID NO: 45 (FIG. 2B). The EcoRI site 
is located in the pGEM-T vector, while the BamHI site is 
located in the MSP coding region. The resulting fragment was 
then digested with XhoI and PstI to provide SEQ ID NO:4 
(FIG. 2A). The reverse complement of SEQ ID NO:4 is 
provided in FIG.3 as SEQID NO:5. SEQID NOS:45 and 5 
were then sequentially cloned into pGEM37f(+) into EcoRI/ 
BamHI and Sall/PstI sites to provide the assembled MSPi 
sequence (SEQID NO:6; FIG. 4; the loop sequence separat 
ing the sense and antisense sequences is underlined). 
The MSPi sequence was removed excised from the plas 
mid by a NcoI/HindIII digest and cloned into pATACTCV 
(Arabidopisis actin-2 promoter (An et al., Strong, constitutive 
expression of the Arabidopsis ACT2/ACT8 actin subclass in 
vegetative tissues. Plant Journal, 10 (1): 107-121 (1996)) to 
provide plasmid (p ATMSPi). The NcoI site is at the 5' end of 
pATMSPi, while the HindIII site is at the 3' end of the plas 
mid. 
Example 2 
RNA Polymerase II Construct Design 
This Example describes the construction of an RNA poly 
merase II RNAi gene. Degenerate primers were used to 
retrieve RNA polymerase II sequence from H. glycines. Since 
H. glycines RNA polymerase II sequence was unknown, the 
primers had to be designed using sequence from C. elegans 
and three other related organisms-Artemia Salina (brine 
shrimp), Helobdella Stagnalis (leech), and Ilyanassa obsolete 
(eastern mud snail). The RNA polymerase II sequences of 
these four organisms were copied into Blockmaker (blocks 
..fhcrc.org). The blocks formed from Blockmaker were then 
copied into Codehop to make degenerate primers. The 
sequences were also copied into Clustalw, which, like Block 
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maker, is a multiple sequence alignment tool. The advantage 
of using Clustalw is that it provides a view of the entire 
alignment of the sequences rather than just blocks of align 
ments. Clustalw also points out regions of the alignment that 
have very tight homology throughout the different organisms. 
Codehop constructs degenerate primers from the blocks 
assembled in Blockmaker. Degenerate primers were chosen 
that had tight homology in the sequence alignments in Clust 
alw, a GC content greater than 45%, degeneracy no greater 
than 16, and amino acids in the 3' end of the primer that are 
coded for by only 1 or 2 codons. 
The degenerate primer pair dRP2L F/dRP2T R1 was cho 
Sen from the degenerate primers made in Codehop. 
dRP2L F primer: 
5 
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(SEQ ID NO: 11) 
RP2 KpnF1B primer: GACGGTACCGGCAGTGTCAATGTTATCCGAAC 
32mer-This primer adds a Kipn I site to the anti 
SeeSee 
fragment (underlined) 
(SEQ ID NO:12) 
ATCGGATCCTCCAATGGTGTGTCCCTCGG 
29mer-This primer adds a Bam HI site to the anti 
SeeSee 
fragment 
RP2 BamRB primer: 
(underlined) 
5'- CCA ACC CTG CAC AAA ATG WSN ATG ATG-3' 27mer. (SEO ID NO : 7) 
dRP2T R1 primer: 5' - CAG AAT TCG GTT CAC TTG RTT YTC RAA-3' 27mer. (SEQ ID NO:8) 
The dRP2L F/dRP2T R1 primer pair successfully ampli 
fied an ~1.0 kilobase fragment from genomic H. glycines 
DNA. The fragment was cloned into a PGEM-T-easy vector 
and five clones were found to have the ~1.0kb fragment. Each 
of the clones were sequenced using SP6 and T7. The sequence 
of the clones was identical. One of the clones was randomly 
chosen for further sequence analysis. The sequence of this 
clone is provided FIG. 5 as SEQID NO:9. 
SEQID NO:9 was used in a blastx search which compared 
it to a protein database (ncbi.nlm.nih.gov/BLAST/). The 
blastx search confirmed that the sequence of clone 6 was RNA 
polymerase II. Thlastx was also used which blasted the 
degenerate nucleotide sequence against a translated database. 
TblastX aided in the location of exons and introns in the 
degenerate sequence. It was necessary to locate the exon 
regions of the sequence because the construct must be 
designed from regions that are transcribed (i.e. exons). From 
tblastX, it was estimated that an exon occurred between base 
pair 555 and base pair 834 in the degenerate sequence. This 
279 base pair exon region is provided in FIG. 6 as SEQ ID 
NO:10. This exon sequence was blasted against a protein 
database (blastx) to confirm that the exon was RNA poly 
merase II and also against the translated database (tblastX) to 
insure that the sequence was indeed an exon. 
Since all plants and mammals possess RNA polymerase II, 
it was necessary to choose an exon that whose sequence 
shows low homology to any other organisms, besides maybe 
C. elegans. If an exon was chosen that demonstrated tight 
homology to other non-target organisms then RNA poly 
merase II may also be shut down in those organisms. When 
the above exon nucleotide sequence was blasted against other 
nucleotide sequence in the database (blastin), very little 
homology was demonstrated with any other organism besides 
C. elegans. From the various blast searches, it was decided 
that the antisense and sense fragments of the construct would 
be designed from this exon region. 
The antisense-sense construct was cloned into the Bam HI 
and Kpn I sites of a puC 119 based vector which possesses a 
35S promoter and nos terminator regions necessary for gene 
expression in Soybeans. Briefly, the primer pair 
RP2 KpnF1B/RP2 BamRB was designed to amplify a 273 
bp antisense fragment from the exon region shown above. 
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The 285 bp fragment resulting from the amplification is pro 
vided in FIG. 7 as SEQ ID NO:13. The amplified fragment 
was cloned into pGEM-T-easy. The fragment was cut out of 
pGEM-T-easy using Kpn I and Bam HI enzymes and subse 
quently cloned behind the 35S promoter in the puC119 based 
vector. The way the sequence is cloned into the vector is 
actually the reverse complement of the above sequence. The 
RP2 BamRB primer adds a BamHI site which is on the 5' end 
of the fragment once cloned into the vector. The 
RP2 KpnF1B primer adds a Kpn I site which is on the 3' end 
of the fragment once cloned into the vector. The sequence of 
the reverse complement is provided in FIG. 8 as SEQ ID 
NO:14. FIG. 9 provides a pictoral representation of the clon 
ing strategy. Positive clones containing the antisense frag 
ment were designated pRS1 KpnF1B-BamRB. 
The sense fragment was then cloned into Kpn I and Sac I 
sites located behind the previously cloned antisense frag 
ment. Briefly, a 243 bp sense fragment was amplified using 
the primer pair RP2 KpnF2B/RP2 SacRB. The forward 
primer RP2 KpnF2B is located 19 bp inside of the 
RP2 KpnF1B primer and the reverse primer RP2 SacRB is 
the same as the RP2 BamRB primer but adds a Sac I site 
instead of a Bam HI site. 
(SEQ ID NO: 15) 
RP2 KpnF2B primer: TGAGGTACCGACGAAGACAGCGGACCATAC 
3 Omer-The primer adds a Kipn I site to the sense 
fragment (underlined) 
(SEQ ID NO: 16) 
RP2 SacRB primer: TTCGAGCTCTCCAATGGTGTGTCCCTCGG 
29mer-The primer adds a Sac I site to the sense 
fragment (underlined) 
The Kpn I and Sac I sites were added to sense fragment so that 
it could be cloned directly behind the antisense fragment. The 
sense fragment is provided in FIG.10 as SEQID NO:17. The 
sequence amplified by these two primers is complementary to 
the sequence of the antisense fragment found in pRS1 
KpnF1B-BamRB clone 14. The sequence in bold is sequence 
that is not complementary between the antisense and sense 
fragments. This non-complementary sequence is necessary 
so that the antisense and sense fragments are able to foldback 
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onto one another and align during transcription, thus forming 
double strand RNA. The cloning strategy is depicted in FIG. 
11. 
Example 3 
Chitin Synthase Constructs 
This Example describes the construction of a chitin syn 
thase RNAi gene. Chitin synthase gene was selected because 
in RNAi experiments by Piano et al. (Piano F. Schetter A.J. 
Mangone M. Stein L. D. Kemphues K J. RNAi analysis of 
genes expressed in the ovary of Caenorhabditis elegans. Cur 
rent Biology 10: 1619) showed that silencing of this gene 
prevents development of nematode progeny (i.e. embryo 
lethal). The spliced sequenced together with Blockmaker 
(blocks.fhere.org), Codehop, and Clustalw to make degener 
ate primers and amplify the chitin synthase sequence from 
Heterodera glycines. This sequence is providing in FIG. 12 
(SEQID NO: 18). Sense and antisense fragments are cloned 
from the underlined region using methods similar to those 
described above. The sense and antisense fragments are then 
cloned into vector as described in Example 2. Primers useful 
for cloning the sense and antisense sequences include the 
following: 
CHSY15.1 F : CCGATGCTTAGGCTGAC (SEQ ID NO:19) 
CHSY21 O. F. CCAGCGGCAGTGATTC (SEQ ID NO: 2O) 
CHSY287 R: AGCACACCTTCTCCAATC (SEQ ID NO:21) 
CHSY355 F: TGGTACCAAAAGTTCGAGTAC (SEO ID NO: 22) 
CHSY4O9 F: CATGTGTTCGGCTGTGT (SEQ ID NO:23) 
CHSYs43 R: ATCGGGTCTTCGCCTTG (SEQ ID NO:24) 
Example 4 
Reduction in the Number of Cysts in Transgenic 
Plants Expressing MSPi Gene 
MSP is the major protein that required for nematode sperm 
motility. If this protein is disrupted, male sterility will result 
and female nematodes will not be fertilized and develop cysts. 
These examples describe experiments wherein soybean 
plants were genetically modified to express the MSPi con 
struct described in Example 1. The results show a significant 
reduction in the amount of cysts from the transgenic plants as 
compared to the non-engineered controls. 
Soybean Somatic embryos were genetically modified using 
a particle gun to contain the pATMSPi construct (MSP 
RNAi), multiplied in tissue culture, and converted to plants. 
Several independent events from two cultivars were recov 
ered containing this construction. The two cultivars were 
“Jack', a partially resistant cultivar, and “Chapman' a sus 
ceptible cultivar. Two bioassays were performed with these 
transgenic lines. 
In the first bioassay the MSP RNAi transgenic plants were 
tested for SCN resistance. Events as well as non-engineered 
controls were transplanted into soil infected with soybean 
cyst nematodes (SCN) and grown in the greenhouse for six 
weeks. Soybean roots were then washed to remove soil and 
debris. SCN cysts were removed from each plant and the 
number of cysts, eggs per cysts and root weight data was 
collected for each replicate. Results are summarized in FIG. 
13-18. 
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In the second bioassay, residual effects of the MSPicon 
struction upon nematodes were evaluated. Cysts from repli 
cates of each event and non-engineered checks were pooled 
independently and ground to release eggs. Eggs were then 
added to sterilized soil at a concentration of 1000 eggs/plant. 
“Flyer', a soybean variety with no resistance to SCN, was 
planted in this infected soil and grown for six weeks. At the 
end of the bioassay the roots were washed and data on cyst 
and egg production and root weight was recorded. Results are 
Summarized in FIGS. 13-17. 
Referring to FIG. 13, data from the first experiment shows 
a slight reduction in the number of cyst per plant when com 
pared to the non-engineered control. In the second experi 
ment even though the eggs harvested from the first experi 
ment were applied to susceptible line (Flyer) at the rate, a 
39.3% reduction in cysts was recorded from eggs harvested 
from the transgenic plants. Inference can be drawn from these 
results that 1) the MSPi construction does inhibit the cysts 
formation at a low level and 2) the effects of the transgene can 
be carried over to the next generation. 
Referring to FIG. 14, data from the first experiment shows 
a 49.4% reduction in the number of cyst per gram of root 
when compared to the non-engineered control. In the second 
experiment a difference (34.0% reduction) was recorded. 
Inference can be drawn from these results that 1) the MSPi 
construction does inhibit the cysts formation at some level 
and 2) the effects of the transgene can be carried over to the 
next generation. 
Referring to FIG. 15, data from the first experiment shows 
a 35.5% reduction in the number of SCN eggs perplant when 
compared to the non-engineered control. In the second 
experiment even though the eggs of the first experiment were 
applied to susceptible line (Flyer) at the same rate (1000 eggs 
per plant) a significant difference (29.0% reduction) was 
recorded in the eggs from the transgenic plants. SCN eggs 
used for inoculation in Experiment 2 originated from eggs 
collected in Experiment 1. SCN eggs from transgenic lines 
were applied at the same rate. Inference can be drawn from 
these results that 1) the MSPi construction does inhibit the 
egg production at Some level and 2) the effects of the trans 
gene was carried over to the next generation of SCN. 
Referring to FIG. 16, data from the first experiment shows 
a 32.5% reduction in the number of SCN eggs per gram root 
when compared to the non-engineered control. In the second 
experiment even though the eggs of the first experiment were 
applied to susceptible line (Flyer) a significant difference 
(25.1% reduction) was recorded. SCN eggs used for inocula 
tion in Experiment 2 originated from eggs collected in 
Experiment 1. SCN eggs from transgenic lines were applied 
at the same rate. Inference can be drawn from these results 
that 1) the MSPiconstruction does inhibit the egg production 
at some level and 2) the effects of the transgene was carried 
over to the next generation of SCN. 
Referring to FIG. 17, data from the first experiment shows 
a small reduction in the number of SCN eggs per cyst when 
compared to the non-engineered control. This reduction was 
not significant when the data was statistically analyzed. This 
trend continued in the second experiment. Inference can be 
drawn from these results that 1) the MSPi construction effect 
the number of eggs per cyst when cyst develop and 2) the 
effects of the transgene on eggs/cysts do not carry over to the 
next generation of SCN. 
In Summary, the results show that soybean plants trans 
formed with the MSPRNAi construction do have significant 
levels of resistance to Soybean cyst nematode. In addition, 
SCN progeny obtained from roots of these plants have a 
reduced ability to infect Susceptible cultivars suggesting 
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retention of the phenotype. Transgenic plants containing the 
MSP RNAi construction presumably cause a significant 
amount of males to become sterile thereby reducing the 
amount of cysts. It also appears the effect of the RNAi mol 
ecules can be seen in the progeny of SCN feeding on the 
nontransgenic plants. 
All publications and patents mentioned in the above speci 
fication are herein incorporated by reference. Various modi 
fications and variations of the described method and system 
of the invention will be apparent to those skilled in the art 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 45 
<21 Os SEQ ID NO 1 
&211s LENGTH: 1257 
&212s. TYPE: DNA 
<213> ORGANISM: Heterodera glycines 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (6) . . (6) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (42) ... (42) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (4 OO) . . (400) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221> NAME/KEY: misc feature 
<222s. LOCATION: (406) ... (406) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (438) ... (438) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (466) . . (.466) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (526) . . (526) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (528) . . (528) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (538.) . . (538) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (558) . . (558) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (565) . . (565) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (568) . . (568) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (1165) . . (1165) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (1167) . . (1167) 
<223> OTHER INFORMATION: n is a, c, g, or t 
38 
without departing from the Scope and spirit of the invention. 
Although the invention has been described in connection with 
specific preferred embodiments, it should be understood that 
the invention as claimed should not be unduly limited to such 
specific embodiments. Indeed, various modifications of the 
described modes for carrying out the invention which are 
obvious to those skilled in molecular biology, plant biology, 
biochemistry, or related fields are intended to be within the 
Scope of the following claims. 



& 4 OO 
45 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (21) ... (21) 
OTHER INFORMATION: n is a, c, g, 
SEQUENCE: 7 
c caa.ccctgc acaaaatgws natgatg 
SEQ ID NO 8 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
<4 OOs, SEQUENCE: 8 
cagaatticgg tt cactitgrt tytcraa 
<210s, SEQ ID NO 9 
LENGTH: 104.7 
TYPE: DNA 
ORGANISM: Heterodera glycines 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (712) . . (712) 
OTHER INFORMATION: n is a, c, g, 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (983) ... (983) 
OTHER INFORMATION: n is a, c, g, 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (996) ... (996) 
OTHER INFORMATION: n is a, c, g, 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (1044) . . (1044) 
<223> OTHER INFORMATION: n is a, c, g, 
<4 OOs, SEQUENCE: 9 
c caa.ccctgc acaaaatgct atgatgggac atcgtgttaa 
aattgttatt ttggattatt acgatagatc ttaccttggit 
tcc.gtcacaa ccc cittacaa togctgattitt gacggggatg 
Caat cactgg agacacgggc agaaataaac galaattgcga 
caccaaatat aaccct tacc ttitt citctaa aaaggcatct 
ggccaacaag C cagtgatgg gaattgttgca ggacacattg 
taaacg.cgac gtttittattg attacgct cq t ct catggat 
ttgggatgga aaaatticcgc agc.ca.gcgat aatcaaaccc 
acaagttgttt acaaagataa titcCaggittt tdtcaaatga 
ttttgttcta actaaggcag togt caatgtt atc.cgaacac 
gaagacagcg gaccatacaa atggattt CC cctggcgaca 
agcgaactitc tict ctdggat aatttgttcc aaaactgttg 
citt cacattgtc.gcattaga attgggtcat caaattgctg 
caaactgtta taaacgcatg gct tct coc gagggacaca 
ttitt acttitt atttacaata attttgttta act ct caggit 
o 
o 
o 
o 
o 
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ggcatgactg ttittatttgc 
cgacttitt cq tatgaatttg 
aaatgaatta gcacct tcc.g 
tggitttittat taatttaaag 
cgacagttaa ttacgc.caca 
accgcagttc gaatgatgac 
ttgttgatgc atttgccaaa 
aagcc actitt ggaccggaala 
aacttitt cot coatt citttg 
att cqaccca to cqgacgac 
c caaagtgct cattgagaac 
gcagaggitt c Cngaalacctt 
cc.gagittata tdccaacata 
c cattggaat tdgtttic cala 
gacacaattig citgat acttic 
27 
27 
6 O 
12 O 
18O 
24 O 
3OO 
360 
54 O 
660 
72 O 
84 O 
9 OO 
46 

49 
<213> ORGANISM: Heterodera glycines 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (123). . (123) 
<223> OTHER INFORMATION: n is a 
<4 OOs, SEQUENCE: 14 
accalatt.cca atggtgttgtc 
ggcatataac toggcagdaa 
t cnggaacct ctdccaacag 
aatgagcact ttggtgtc.gc 
cggatgggtc gaatgtgttc 
<210s, SEQ ID NO 15 
&211s LENGTH: 30 
&212s. TYPE: DNA 
Cct cqgcgag 
tittgatgacc 
ttittggaaca 
Caggggaaat 
ggata acatt 
aagc.catgcg 
Caatt Ctaat 
aattatcCCa 
c catttgtat 
gacactgcc 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 15 
tgaggt accg acgalagacag 
<210s, SEQ ID NO 16 
&211s LENGTH: 29 
&212s. TYPE: DNA 
cggaccatac 
Synthetic 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 16 
titcgagct ct c caatggtgt 
<210s, SEQ ID NO 17 
&211s LENGTH: 279 
&212s. TYPE: DNA 
gtc.cct cig 
Synthetic 
<213> ORGANISM: Heterodera glycines 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (157) . . (157) 
<223> OTHER INFORMATION: n is a 
<4 OOs, SEQUENCE: 17 
ggcagtgtca atgttatc.cg 
tacaaatgga titt cocctgg 
gggataattt gttccaaaac 
ttagaattgg gtcatcaaat 
gcatggct tc. tcgc.cgaggg 
<210s, SEQ ID NO 18 
&211s LENGTH: 563 
&212s. TYPE: DNA 
aacacatt cq 
cgacaccaaa 
tgttggcaga 
tgctg.ccgag 
acacaccatt 
acc catc.cgg 
gtgct cattg 
ggttcCngaa 
ttatatgc.ca 
ggaattggit 
<213> ORGANISM: Heterodera glycines 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (507) ... (507) 
<223> OTHER INFORMATION: n is a 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (52O) ... (52O) 
<223> OTHER INFORMATION: n is a 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
C, g, or t 
C, g, or t 
US 7,803,984 B2 
- Continued 
tittataa.ca.g 
gcgacaatgt 
gagagaagtt 
acgacga aga 
agalacagcga 
acct tott ca. 
acatacaaac 
tttgtatgtt 
gaagaaggitt 
cgctgttctic 
citt cqtcgt.c 
Cagcggacca 
act tot ct ct 
cattgtc.gca 
tgttataaac 
6 O 
12 O 
18O 
24 O 
279 
3 O 
29 
6 O 
12 O 
18O 
24 O 
279 
50 
<222s. LOCATION: (526). 
51 
. (526) 
<223> OTHER INFORMATION: n is a 
<4 OOs, SEQUENCE: 18 
Caagaaacga tiggtcc cagg 
Ctcacatttg agcgtagaag 
gtggaatctg. tcaataatt 
Ctcgc.cattg atggcgattic 
atgaacttga aaa.gcgacgt. 
gtgctatoct tcc cattaat 
cCaaaagttc gagtacgcaa. 
Ctgtgttttgttgc.ccc.cg 
caatgtgatg cacaaataca 
gatcaaggcg aagaccc.gat 
<210s, SEQ ID NO 19 
&211s LENGTH: 17 
&212s. TYPE: DNA 
tgatgtacat 
acaaacaatt 
caatgttcgc 
caaatticgaa 
ggtgaattitc 
tcqcc cattg 
gtagcttct c 
c caaaantgc 
gga 
gtacttitttg 
gCaggtottt 
accatgctt 
Ccagcggcag 
tgcggaagaa 
ttaccatt co 
gttcCaaaag 
tctgttt cqt 
citc.cgaaccin 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 19 
cc.gatgctta ggctgac 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 16 
&212s. TYPE: DNA 
Synthetic 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 2O 
Ccagcggcag tatto 
<210s, SEQ ID NO 21 
&211s LENGTH: 18 
&212s. TYPE: DNA 
Synthetic 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 21 
agcacaccitt citccaatc 
<210s, SEQ ID NO 22 
&211s LENGTH: 21 
&212s. TYPE: DNA 
Synthetic 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
<4 OOs, SEQUENCE: 22 
tggtaccalaa agttctgagta 
<210s, SEQ ID NO 23 
&211s LENGTH: 17 
&212s. TYPE: DNA 
c 
Synthetic 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
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Ctcgggcatc 
tgagcct aaa 
aggctgacaa 
tgatt cqtct 
tccatcc.gat 
cCagggg.tca 
gctgctgagc 
gctitctgctic 
acgacnattt 
gaattatgga 
ttttgccctic 
Cacatatatt 
tttacatctg 
tggagalaggt 
tggitttggta 
atgtgttcgg 
t catggatga 
tgttcagtat 
6 O 
12 O 
18O 
24 O 
3OO 
360 
54 O 
563 
17 
16 
18 
21 
52 
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- Continued 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (76) . . (76) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<4 OOs, SEQUENCE: 42 
tctgtttcgt gcttctgctic ticatggatga caatgtgatg cacaaataca ccaaaantgc 
citcc.gaac Cn acgacnattt togttcagtat gat caaggcg 
SEQ ID NO 43 
LENGTH: 1.OO 
TYPE: DNA 
ORGANISM: Heterodera glycines 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (57) . . (57) 
OTHER INFORMATION: n is a, c, g, or t 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (70) . . (70) 
OTHER INFORMATION: n is a, c, g, or t 
FEATURE: 
NAMEAKEY: misc feature 
LOCATION: (76) . . (76) 
OTHER INFORMATION: n is a, c, g, or t 
<4 OOs, SEQUENCE: 43 
tctgtttcgt gcttctgctic ticatggatga caatgtgatg cacaaataca ccaaaantgc 
citcc.gaac Cn acgacnattt togttcagtat gat caaggcg 
<210 SEQ ID NO 44 
&211s LENGTH: 55 
&212s. TYPE: DNA 
<213> ORGANISM: Heterodera glycines 
<4 OOs, SEQUENCE: 44 
tctgtttcgt gcttctgctic ticatggatga caatgtgatg cacaaataca ccaaa 
<210s, SEQ ID NO 45 
&211s LENGTH: 389 
&212s. TYPE: DNA 
<213> ORGANISM: Heterodera glycines 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (248) ... (248) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (254) ... (254) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (286) ... (286) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (314) ... (314) 
<223> OTHER INFORMATION: n is a, c, g, or t 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (353) ... (383) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<4 OOs, SEQUENCE: 45 
ggat CCtatc atgtcCatgt taggtgacg aag catcCtt C catcagacg ttgtactica 
tcggcaagtt Cttgcggcgc accatc.ccgt. Ct.ccctggala C cact cagc titgaacgtgg 
gcacgttggit C cacgc.cacg gtcacacggt Citcc ttggt gtc.ct cqctg ccdgggtca 
6 O 
6 O 
55 
6 O 
12 O 
18O 
24 O 
62 
US 7,803,984 B2 
63 64 
- Continued 
aggcgt Cinca gaanacggcc acgttgacag attcc tittgg gcc.ganic act CC9tc.cggcg 
ggttcatgtt gatncgct tc ggtttggtgg tottgaaggc Ctgcagc.cat gginnnn.nnnn 
nnngaattic 
We claim: 
1. A transgenic plant comprising a nucleic acid sequence 
having a sense sequence linked to its complementary anti 
sense sequence and encoding a double stranded RNA that 
inhibits expression of a Heterodera glycines embryonic lethal 
phenotype gene, wherein the sense or antisense sequence 
comprises SEQID NO: 1, SEQID NO:9 or SEQID NO: 18, 
wherein nematodes ingesting said double stranded nematode 
RNA do not proliferate, and wherein said transgenic plant 
exhibits increased resistance to soybean cyst nematodes as 
compared to a control plant. 
2. Seed from the transgenic plant of claim 1, wherein said 
seed comprise said nucleic acid sequence. 
3. A vector comprising a nucleic acid sequence having a 
sense sequence linked to its complementary anstisense and 
encoding a double stranded RNA sequence that inhibits 
expression of a Heterodera glycines embryonic lethal pheno 
type gene, wherein said sense sequence orantisense sequence 
comprises SEQID NO: 1, SEQID NO:9 or SEQID NO: 18; 
and wherein nematodes ingesting said double stranded nema 
tode RNA do not proliferate. 
4. The vector of claim 3, wherein said nucleic acid 
sequence comprises a sense sequence linked to its comple 
mentary antisense sequence, said nucleic acid sequence being 
operably linked to a plant promoter. 
5. The vector of claim 3, wherein said nucleic acid 
sequence comprises a sense sequence and its complementary 
antisense sequence separated by a loop sequence. 
6. The vector of claim 4, wherein said promoter is a tissue 
specific promoter. 
7. The vector of claim 4, wherein said promoter is a con 
stitutive promoter. 
8. The vector of claim 3, wherein said nucleic acid 
sequence comprises a sense sequence and its complementary 
antisense sequence each operably linked to separate promot 
CS. 
10 
15 
25 
30 
35 
40 
45 
3OO 
360 
389 
9. A transgenic Soybean plant comprising the vector of 
claim 3; said transgenic soybean plant exhibits increased 
resistance to soybean cyst nematodes as compared to a con 
trol plant. 
10. A method for controlling Heterodera glycines compris 
ing providing a transgenic Soybean plant comprising a nucleic 
acid sequence having a sense sequence linked to its comple 
mentary anstisense and encoding a double stranded RNA that 
inhibits expression of a Heterodera glycines embryonic lethal 
phenotype gene, wherein the proliferation of nematodes feed 
ing on said plant is reduced as compared to nematodes feed 
ing on non-transgenic plant and wherein said sense sequence 
or antisense sequence comprises SEQ ID NO: 1, SEQ ID 
NO:9 and SEQID NO:18. 
11. The method of claim 10, wherein said nucleic acid 
sequence is on a vector. 
12. The method of claim 11, wherein said nucleic acid 
sequence comprises a sense sequence and its complementary 
antisense sequence operably linked to a plant promoter. 
13. The method of claim 12, wherein said sense sequence 
and said antisense sequence are operably linked to the same 
promoter. 
14. The method of claim 12, wherein said promoter is a 
tissue specific promoter. 
15. The method of claim 12, wherein said promoter is a 
constitutive promoter. 
16. The method of claim 10, wherein said sense sequence 
and said antisense sequence are separated by a loop sequence. 
17. A transgenic plant comprising a nucleic acid encoding 
a double stranded RNA that causes decreased proliferation of 
Soybean cyst nematodes feeding on said transgenic plant as 
compared to soybean cyst nematodes feeding on non-trans 
genic plants, wherein one strand of said double stranded RNA 
is complementary to a nematode embryonic lethal phenotype 
gene, and wherein said one strand comprises a sequence 
selected from the group consisting of SEQID NO: 1, SEQID 
NO:9 and SEQID NO: 18. 
k k k k k 
